⚡ Quick Start — If You Read Nothing Else

The 10 most important things to know about Parkinson's disease dementia.

Parkinson's disease dementia (PDD) means thinking and memory changes that develop after someone has had Parkinson's disease for some time. It is part of the “Lewy body” family of conditions and is common as Parkinson's advances — it is not your fault and it is not a separate disease you “caught.”
The thinking changes in PDD look different from Alzheimer's. Early on, memory is often relatively preserved; what stands out is trouble with attention and concentration that fluctuates (good days and bad hours), slowed thinking, difficulty planning, and visuospatial problems. Visual hallucinations are common.
There is one FDA-approved medicine specifically for PDD: rivastigmine. It is a “cholinesterase inhibitor” that can modestly improve attention, thinking, and hallucinations. It does not cure or stop the disease, but it can help meaningfully.
Some common medicines are dangerous in PDD — this is critical. People with Lewy body conditions have severe sensitivity to antipsychotic drugs. Older antipsychotics (like haloperidol) and many newer ones, plus certain anti-nausea drugs (metoclopramide, prochlorperazine), can cause life-threatening reactions and must be avoided. Make sure every doctor knows the diagnosis.
Hallucinations and delusions can often be improved safely. The first step is usually reducing or simplifying medicines that can trigger them; when a drug is needed, pimavanserin, low-dose quetiapine, or clozapine are used cautiously — never the dangerous antipsychotics above.
Fluctuations are part of the illness, not “faking.” Alertness and clarity can swing widely within a day. Recognizing this prevents frustration and helps you plan important conversations for the person's best times.
Treat the reversible things first. Infections (especially urinary), dehydration, poor sleep, pain, constipation, and certain medications can all worsen thinking quickly. Sudden confusion deserves a prompt medical check, not just “the dementia getting worse.”
Non-thinking symptoms matter too. Acting out dreams (REM sleep behavior disorder), dizziness on standing (low blood pressure), depression, and sleep problems are common and treatable, and managing them improves quality of life.
Caregivers are central — and need support. Managing fluctuations, hallucinations, safety, and medications is demanding. Support, respite, and planning are not luxuries; they protect both of you.
There is no cure yet, but a lot can be done. Thoughtful treatment, careful medication safety, attention to reversible causes, and good support genuinely improve daily life for patients and families.

▼ Collapse

Understanding Parkinson's Disease Dementia

When someone who has lived with Parkinson's disease begins to have trouble thinking, concentrating, or remembering, it is frightening and confusing for the whole family. This guide explains what Parkinson's disease dementia is, how it is diagnosed, what treatments genuinely help, which medicines are dangerous and must be avoided, and how to navigate care — in plain language, organized by where you are in the journey.

Parkinson's disease dementia (PDD) is a decline in thinking abilities significant enough to affect daily life that develops in a person who already has established Parkinson's disease. It belongs to the Lewy body disease family, named after the abnormal clumps of a protein called alpha-synuclein that build up in the brain. Cognitive change is common in Parkinson's over time — many people develop at least mild changes, and a substantial proportion progress to dementia as the disease advances.

Reasons for genuine hope — even without a cure. There is one approved medicine for PDD thinking symptoms, effective ways to treat hallucinations safely, and a long list of reversible problems that, when fixed, can restore clarity. Careful medication management avoids serious harm, and good support dramatically improves quality of life. New diagnostic tools and a research pipeline are advancing. A diagnosis of PDD is serious, but there is a great deal that can be done.

PDD and dementia with Lewy bodies — two sides of one coin

You may hear about dementia with Lewy bodies (DLB), which is closely related to PDD. The biology is very similar; the difference is timing. Doctors use a practical “1-year rule”: if dementia begins after a person has had Parkinson's movement problems for a year or more, it is called PDD; if thinking problems and movement problems begin around the same time (dementia first or within a year), it is called DLB. The treatments and safety precautions are largely the same, so this distinction matters more for naming and research than for day-to-day care.

What PDD looks like

The pattern of PDD is distinctive and differs from Alzheimer's disease:

Attention and concentration that fluctuate — alertness can vary markedly from day to day or even hour to hour, sometimes mistaken for drowsiness or “not trying.”
Slowed thinking and trouble with planning and multitasking (so-called executive function).
Visuospatial difficulty — judging distances, navigating, or interpreting what is seen.
Visual hallucinations — commonly seeing people or animals that are not there; often non-threatening at first.
Memory is often relatively preserved early on, especially with cues — different from the prominent forgetting of Alzheimer's.

A practical way families describe the difference from Alzheimer's: in PDD, the person often still knows things but has trouble accessing and using them efficiently — retrieving a word, keeping track of a multi-step task, or making sense of a busy visual scene — and this varies with their level of alertness. With a cue or a prompt, memory often comes back, whereas in Alzheimer's the information is more truly lost. Visual hallucinations — commonly seeing people, children, or animals — are a hallmark and are often non-threatening at first, and many people retain insight that they are not real. Misperceptions (mistaking a coat on a chair for a person) and a sense that someone is present are also common. Recognizing these as features of the illness, not signs of “going crazy,” helps everyone respond calmly.

Why it happens

In Parkinson's disease, alpha-synuclein protein misfolds and accumulates in brain cells, first affecting movement-control regions and, over time, spreading to areas involved in thinking, attention, and perception. The loss of a brain chemical called acetylcholine is especially important in PDD — which is exactly why cholinesterase inhibitor medicines (which boost acetylcholine) can help. Understanding this also explains why drugs that block acetylcholine (anticholinergics) tend to worsen thinking and should be minimized.

First steps after a diagnosis

If you have just received this diagnosis, a few early steps set you up well. First, make sure the diagnosis is documented and that every clinician, the pharmacy, and any hospital know about the antipsychotic sensitivity — ask for it to be added to the medical record and allergy list, and carry a card listing medicines to avoid. Second, ask for a thorough medication review to identify anything that could be clouding thinking. Third, ask whether rivastigmine is appropriate. Fourth, connect with support — the Lewy Body Dementia Association and Parkinson's organizations offer education and care-partner help that families consistently find invaluable. Fifth, begin (gently, over time) the planning conversations — legal, financial, and care preferences — while the person can take part. You do not have to do all of this at once; pacing it reduces overwhelm.

How common is it, and when does it happen?

Cognitive change is one of the most common non-movement features of Parkinson's disease over the long term. Many people with Parkinson's develop at least mild cognitive changes, and studies suggest a large proportion go on to develop dementia after living with the disease for many years — risk rises with age and with longer disease duration. This does not mean everyone with Parkinson's will develop dementia, and the timing varies enormously from person to person. Mild changes (sometimes called PD-MCI, mild cognitive impairment) may come first and do not always progress quickly. Knowing that cognitive change is a recognized part of the illness — not a personal failing or a separate catastrophe — helps families respond with planning rather than fear.

How PDD Progresses: A Realistic Guide to the Disease Trajectory

PDD is a progressive condition, but the pace of progression varies widely between individuals. Some people with PDD remain in the mild-to-moderate stage for many years; others progress more quickly. Understanding the general trajectory — while recognizing that no prediction is exact — helps families plan for care needs, legal matters, and emotional readiness at each stage.

The earliest stage of PDD is sometimes called Parkinson’s Disease Mild Cognitive Impairment (PD-MCI). People in this stage notice changes in memory or thinking, but remain largely independent. Typical features include:

Slowed thinking and processing speed — it takes longer to respond to questions, follow complex instructions, or complete multi-step tasks
Visuospatial difficulties: trouble judging distances, navigating unfamiliar spaces, or reading maps
Word-finding difficulties (tip-of-the-tongue phenomenon)
Attention fluctuations — concentration is harder, especially with background noise or distractions
Subtle short-term memory problems, though usually less severe than in Alzheimer’s disease at the same stage

At this stage, most people can manage their own medications, finances, and daily routines with minimal assistance. The main care tasks are: (1) simplifying complex tasks, (2) addressing modifiable risk factors (poor sleep, cardiovascular risk, medication optimization), and (3) getting legal and financial documents in place while the person retains full decision-making capacity.

In moderate PDD, cognitive impairment becomes clearly noticeable and begins to affect independence with daily life. This is often the longest stage. Features include:

Cannot safely manage medications independently — pill organizers and caregiver oversight or administration are now needed
Hallucinations become more common (visual hallucinations in 50–80% of people with PDD at this stage) and may begin to cause distress
Financial and driving safety are significantly impaired — these tasks require oversight or transfer to family
Falls become more frequent due to the combination of motor impairment, cognitive impairment affecting safety awareness, and medication effects
Behavioral symptoms emerge or worsen: apathy (very common), depression, sleep disruption including REM sleep behavior disorder
Need for assistance with complex ADLs (bathing, dressing, meal preparation) increases

Care planning in moderate PDD typically involves: regular neurology follow-up to adjust medications, consideration of rivastigmine and pimavanserin (if not already started), fall prevention home assessment, caregiver education and support, and explicit goals-of-care discussions.

In advanced PDD, the person requires assistance or complete dependence for most activities of daily living. This stage overlaps significantly with when families begin thinking about residential care and hospice. Features include:

Very limited mobility, often chair- or bed-bound much of the day
Complete dependence for all personal care (bathing, dressing, toileting)
Swallowing difficulties (dysphagia) requiring modified diet textures or thickened liquids, and careful positioning during meals
Limited verbal communication, though emotional responsiveness and ability to recognize family members may persist longer than verbal ability
Recurrent infections (pneumonia from aspiration, urinary tract infections) that cause acute confusional episodes
Weight loss despite adequate nutritional support

The most common causes of death in PDD are aspiration pneumonia, pulmonary embolism (from immobility), and systemic infections. Most families find the most meaningful care focus at this stage shifts entirely to comfort, dignity, and quality of time spent together.

Several factors are associated with faster or slower progression in PDD, though none of them is fully predictive at the individual level:

Earlier age at onset of cognitive symptoms is generally associated with slower motor but sometimes faster cognitive decline
GBA gene variants (Gaucher disease-related genetic changes) are associated with faster cognitive progression
Hallucinations appearing early in the disease course are a marker of more rapid dementia progression
REM sleep behavior disorder present for many years before diagnosis may correlate with somewhat different disease biology
Vascular risk factors (high blood pressure, diabetes, high cholesterol, smoking) that are well-controlled may slow mixed pathology contributions to cognitive decline
Physical exercise is consistently associated with slower functional decline in observational studies; the effect size is meaningful, though hard to quantify precisely
Comorbid depression and anxiety that are not adequately treated worsen cognitive performance independently of underlying PDD pathology

What to expect over time

PDD is a progressive condition, meaning it gradually worsens, but the pace varies widely and is often slow, measured in years. Importantly, the path is rarely a straight line: there are better and worse periods, and sudden dips frequently turn out to be caused by something treatable (an infection, dehydration, a medication) rather than a permanent step down. Knowing this helps families avoid two traps — despairing at a bad week that may improve, and dismissing a sudden change that actually needs medical attention. Treatment cannot stop the underlying progression yet, but it can ease symptoms, prevent avoidable setbacks, and protect quality of life. Planning ahead during clearer periods — for care preferences, safety, and support — gives the whole family more control and less crisis. Throughout, the goals are comfort, safety, dignity, connection, and supporting the people doing the caring.

Understanding the Day-to-Day Experience of PDD

Parkinson's disease dementia is not a fixed or static condition. It is defined in part by variability — not just between people, but within the same person across hours and days. Understanding this helps families set realistic expectations and respond constructively when a bad day arrives.

On a good day, someone with PDD may carry a conversation, recall recent events reasonably well, and participate in familiar activities. They may seem nearly like their old self, especially for an hour or two after waking or after their Parkinson's medication takes effect. On these days, families sometimes wonder if the diagnosis was right, or feel hopeful that the disease is not progressing.

On a bad day, the same person may be very drowsy, confused, unable to recognize familiar places or follow simple instructions, or may see or hear things that are not there. These fluctuations are a core feature of Lewy body dementia — they are not caused by a new stroke, a medication error, or caregiver failure. They are built into the disease process itself.

Patterns caregivers often notice:

Morning confusion: Worse cognitive function in the morning, sometimes improving over 1–2 hours after waking and after Parkinson's medication takes effect
Afternoon dip: A period of drowsiness or confusion in the early afternoon, especially if sleep at night was disrupted
Sundowning: Increased confusion, agitation, or hallucinations in the late afternoon and evening — common in all dementias, especially PDD
Day-to-day variability: Some days are inexplicably much better or worse than others, without an obvious trigger
Good days after bad days: A clear, alert day can follow two or three confused days. This is characteristic of Lewy body dementia and is not a reliable sign of recovery

Visual hallucinations — seeing things that are not there — occur in up to 60–75% of people with PDD or DLB. They are one of the most defining features of Lewy body dementia. Understanding their nature helps caregivers respond more effectively.

What PDD hallucinations typically look like:

Most commonly: formed visual hallucinations of people, children, or animals. These images are usually vivid, non-threatening, and detailed — a person may see children playing in the corner of the room, or a familiar figure sitting in a chair
Sometimes: animals, insects, or moving patterns on the walls or floor
Less commonly: threatening images (strangers in the home) — these are more distressing and may require medication
The person with PDD is often partially aware that the images may not be real. This partial insight is more common in early-to-moderate PDD

How to respond:

Don't argue or try to prove the hallucination is not real. Arguing increases distress without changing the experience. Instead, say something like "I can see you're seeing something. I don't see it, but I believe it feels real to you. Are you scared?"
Acknowledge the feeling, not the content. If they seem frightened, reassure them of their safety. If they are not distressed by the hallucination, it may not require intervention
Check for triggers: Poor lighting, mirrors, shadows, and busy visual environments can trigger or worsen hallucinations. Improving lighting and simplifying the visual environment can reduce frequency
Report to the neurologist if hallucinations become frightening or are accompanied by paranoid beliefs. Pimavanserin or dose adjustments to Parkinson's medications may be needed
Never give traditional antipsychotics (such as haloperidol, olanzapine, or risperidone) without neurologist guidance. These can cause severe and sometimes irreversible worsening of Parkinson's motor symptoms in people with Lewy body pathology

One of the most useful things a caregiver can do is keep a simple daily log for 2–4 weeks before a neurology appointment. Neurologists cannot directly observe the fluctuations that occur at home — the person with PDD often appears relatively well in a clinic environment due to the novelty and stimulation of the visit. A home log gives the doctor the information needed to make treatment decisions.

What to track (a simple notebook or phone notes app works well):

Time of each Parkinson's medication dose (which medication, what dose, exact time)
Motor "on" and "off" periods — roughly when they move well vs. when they are stiff, slow, or frozen
Cognitive fluctuations — note any 1–2 hour windows of unusual clarity or unusual confusion
Hallucination episodes — time, content, duration, level of distress
Sleep: what time to bed, any episodes of shouting/movement during sleep (RBD), what time awake, daytime naps
Falls or near-falls: time of day, what they were doing, any connection to medication timing
Behavioral changes: agitation, paranoia, repetitive questions, exit-seeking

Bring this log to every neurology visit. It is more useful than trying to remember events, and it helps the neurologist identify patterns — for example, whether confusion spikes are related to low medication (wearing-off effect) or to over-medication (too much dopamine, which can also worsen cognition and hallucinations).

What it can feel like, day to day

For the person, PDD can feel like a mental “fog” that comes and goes, trouble following conversations or keeping track of steps in a task, and unsettling experiences of seeing things others don't. For families, the fluctuations can be the most confusing part — a loved one who is sharp and engaged one afternoon and distant or confused the next, which can be mistaken for stubbornness or “not trying.” Understanding that this variability is part of the biology of the illness changes how everyone copes: it reduces frustration, helps you time important conversations for good moments, and reminds you that a bad day is not necessarily a permanent decline.

Common questions, honest answers

“Is this the same as Alzheimer's?” No. The biology and the pattern differ — PDD affects attention, planning, and visual-spatial skills more than early memory, and it carries the critical antipsychotic-sensitivity risk that Alzheimer's does not to the same degree.
“Did the Parkinson's medicines cause this?” The medicines did not cause the dementia, but some can worsen confusion or trigger hallucinations, which is why doctors carefully review and sometimes simplify them.
“Will rivastigmine cure it?” No — it can modestly improve attention, thinking, and hallucinations and is well worth trying, but it does not stop the disease.
“He suddenly got much more confused — is the dementia racing ahead?” Often not. Sudden worsening usually points to something treatable — an infection, dehydration, constipation, pain, poor sleep, or a new medicine — and should be checked promptly.
“Are the hallucinations dangerous?” Mild hallucinations the person knows aren't real are often managed with reassurance and medication review; frightening or worsening hallucinations should be reported and can usually be improved safely.
“What's the one thing we must get right?” Make sure every clinician knows about the antipsychotic sensitivity, so a dangerous drug is never given — especially in an emergency room or hospital.

The biology, a little deeper

Parkinson's disease and PDD are both “synucleinopathies” — conditions defined by the misfolding and clumping of a protein called alpha-synuclein into deposits known as Lewy bodies. In Parkinson's, these deposits first disrupt deep brain regions that control movement, which is why the earliest symptoms are tremor, stiffness, and slowness. Over years, the process tends to spread to the outer brain regions (the cortex) that handle attention, planning, and visual processing — producing the cognitive symptoms of PDD. Two chemical-messenger systems are especially affected: dopamine (movement) and acetylcholine (attention and thinking). The loss of acetylcholine is a major reason for the cognitive and visual-hallucination symptoms, and it is precisely why medicines that raise acetylcholine (the cholinesterase inhibitors) can help, and why medicines that block it (anticholinergics) make things worse. This biology — not anything the person did — drives the illness, and understanding it makes the treatment choices make sense.

Questions to ask your doctor

Are these thinking changes consistent with Parkinson's disease dementia, and how was that decided?
Could anything reversible — medications, infection, sleep, mood — be making it worse right now?
Which of my current medicines could be harming thinking, and can any be reduced?
Should we start rivastigmine, and what should we expect from it?
Which medicines must be avoided because of neuroleptic sensitivity?

Diagnosis & Workup

There is no single test for PDD; the diagnosis is made by an experienced clinician who puts together the history, an examination, cognitive testing, and tests to rule out other causes. Understanding the process helps you participate.

How the diagnosis is made

Doctors use established criteria (from the international Movement Disorder Society) that look for dementia developing in someone with established Parkinson's disease, with the characteristic pattern of attention, executive, and visuospatial difficulty. The evaluation typically includes:

A careful history — from both the patient and someone who knows them well — about when thinking changes began relative to the movement disorder, and how they fluctuate.
Cognitive testing — brief office tests (such as the MoCA) or fuller neuropsychological testing to map strengths and weaknesses.
A medication review — because many drugs (including some used for Parkinson's, bladder, sleep, or allergies) can cloud thinking.
Blood tests and sometimes brain imaging — to exclude other contributors (thyroid problems, vitamin deficiencies, stroke).

Always rule out reversible causes first. A relatively sudden worsening of confusion is often not the dementia itself but a treatable problem — a urinary or chest infection, dehydration, constipation, pain, poor sleep, or a new medication. These should be looked for and treated before concluding the dementia has progressed.

This point is worth dwelling on, because it changes outcomes. People with PDD are unusually vulnerable to delirium — an abrupt, often dramatic worsening of confusion triggered by a physical stress. The most common triggers are infections (especially urinary tract infections, which can be silent in older adults), dehydration, constipation, uncontrolled pain, sleep deprivation, low sodium or other metabolic problems, and newly added medications. The crucial message for families is to resist the assumption that a sudden change is “just the dementia.” A prompt evaluation — checking for infection, reviewing recent medication changes, and correcting dehydration or constipation — can often restore the person much of the way back to their previous baseline. Keeping a simple record of the person's usual best level of functioning helps the medical team recognize when something acute has changed.

Cognitive testing, explained

Cognitive testing sounds intimidating but is simply a structured way to map strengths and weaknesses. A brief office test like the MoCA takes about 10–15 minutes and samples attention, memory, language, and visuospatial skills; it is more sensitive than older tests to the kind of difficulties seen in PDD. When the picture is complex — for example, distinguishing PDD from depression, Alzheimer's, or medication effects — fuller neuropsychological testing (a few hours with a psychologist) gives a detailed profile. Results are most useful when compared over time, so a baseline is valuable. Bring a list of all medications and supplements to the visit, and have someone who knows the person well describe day-to-day changes; that collateral history is often the most important part of the assessment.

Specialized tests

In selected cases, doctors may use additional tools:

DaTscan (a dopamine-imaging scan) can support a Lewy body diagnosis when the picture is unclear.
Alpha-synuclein seed amplification assay (SAA) — a newer test (on spinal fluid or skin) that detects the misfolded protein behind Lewy body disease with high accuracy. It is increasingly used in research and specialty centers to confirm the underlying biology, though it does not by itself diagnose dementia.
MIBG cardiac scan — used more in some countries (notably Japan) to support the diagnosis.

It is worth knowing that these specialized tests are usually supportive rather than definitive: PDD remains primarily a clinical diagnosis based on the history and examination, and most people do not need every test. A DaTscan can confirm that the dopamine system is affected (consistent with Lewy body disease) but cannot by itself separate Parkinson's, PDD, and dementia with Lewy bodies from one another. The newer seed amplification assay is an exciting advance because it detects the actual misfolded protein behind the disease, and its use is growing in specialist and research settings; even so, it confirms the underlying biology rather than measuring how much the dementia has progressed. Ask your clinician whether any specialized test would actually change your treatment before pursuing it — in many cases, the clinical picture is clear enough to proceed.

One thing that often reassures families: there is usually no urgent “test” deadline. Unlike a sudden stroke, PDD is recognized over time through the pattern of change, so it is reasonable to take the steps in order — review medications, check for reversible problems, do cognitive testing, and rule out other causes — rather than rushing to scans. The most valuable information often comes not from a machine but from a careful description, by someone who knows the person well, of what has changed and how it fluctuates. Keeping a brief diary of good and bad periods, new symptoms, and medication changes can genuinely help the clinician reach the right diagnosis and plan.

Understanding Your Cognitive Test Results

When you or a family member receives a cognitive assessment, the results can feel abstract and hard to interpret. This section explains what the most common tests measure, how results are used, and what score ranges actually mean for day-to-day function and care planning.

A neuropsychological evaluation for suspected PDD assesses multiple cognitive domains. The profile of which domains are impaired (and which are relatively preserved) helps confirm the diagnosis and guides care planning. The domains tested include:

Attention and concentration: The ability to focus on a task and sustain that focus. Impaired attention is one of the earliest and most prominent features of PDD — more severe than in Alzheimer's disease at a comparable cognitive stage
Executive function: Planning, organizing, sequencing, and solving novel problems. Early executive dysfunction in PDD affects complex activities of daily living (managing finances, following multi-step recipes, scheduling) while basic self-care is still intact
Visuospatial abilities: Judging spatial relationships, copying geometric figures, interpreting what is seen. PDD causes prominent visuospatial impairment early, which distinguishes it from Alzheimer's disease (where language and memory are more affected early)
Memory: In PDD, verbal memory is impaired but often less severely than in Alzheimer's disease. Importantly, people with PDD tend to benefit more from cues and prompts (e.g., being given the first letter of a word they can't retrieve), while people with Alzheimer's disease often cannot use cues effectively even if given them
Language: Generally relatively preserved in early-to-moderate PDD compared to Alzheimer's disease, though word-finding difficulties (anomia) may occur
Processing speed: The speed of thinking and responding. Slowed processing is universal in PDD and often more severe than in other dementias

Cognitive test scores are most useful when tracked over time. A single score tells you where someone is now; the change in scores between visits (typically 6 or 12 months apart) tells you about the rate of progression. Neurologists and neuropsychologists use these scores to:

Confirm the diagnosis and stage of dementia (mild, moderate, or severe)
Assess whether cognitive medications (rivastigmine, memantine) are having benefit or whether the dose should be adjusted
Determine when driving is no longer safe
Identify when certain tasks (managing finances, managing medications independently) need to be transferred to a caregiver
Support legal planning conversations about when cognitive capacity may be affected

Interpreting the numbers: For the MoCA (0–30 scale), the typical thresholds used clinically are: 26–30 = normal; 18–25 = mild cognitive impairment or mild dementia; 10–17 = moderate dementia; <10 = severe dementia. These are approximate guides, not rigid cutoffs. A score in the mild range with preserved daily function has very different implications than the same score in someone who can no longer manage medications independently.

Performance variability: Because cognitive fluctuations are characteristic of PDD, a person may perform somewhat differently on tests done on different days. A single testing session captures a snapshot; the neuropsychologist will note whether the results seemed consistent with the history being reported at home.

Which cognitive domains were most affected in the testing?
How does this profile fit with PDD versus other causes of dementia?
What is the expected rate of change? Should we retest in 6 months or 12 months?
At what score level does driving become unsafe, in your clinical judgment, given this patient's other symptoms?
Are there specific activities where the level of impairment means supervision is now needed?
When should we involve a neuropsychologist for a full evaluation rather than just bedside screening?

Distinguishing PDD from look-alikes

Part of the diagnostic work is making sure the picture really is PDD and not something that looks similar but is managed differently. Depression in Parkinson's can mimic dementia (“pseudodementia”) and is very treatable, so it is actively considered. Alzheimer's disease can coexist with or resemble PDD but has a different pattern (prominent early memory loss). Medication effects — especially anticholinergic and sedative drugs — can closely imitate dementia and may be reversible. Other parkinsonian conditions (such as progressive supranuclear palsy or multiple system atrophy) and structural problems like normal-pressure hydrocephalus or strokes are also weighed. Getting this right matters because it changes treatment, prognosis, and which medicines are safe.

Questions to ask your doctor

What testing will you do, and what are you trying to rule out?
Could any reversible problem be contributing right now?
Is the pattern more like Parkinson's dementia, dementia with Lewy bodies, or Alzheimer's — and does it change treatment?
Would a specialized test (DaTscan, SAA) add anything useful in my case?

Treatment

There is no cure for PDD yet, but several treatments meaningfully help thinking, behavior, and quality of life — and, just as importantly, careful management avoids serious harm.

The honest headline. Today's treatments are symptomatic — they can improve attention, thinking, hallucinations, and other symptoms, but they do not stop the underlying disease. Used well, alongside attention to reversible causes and medication safety, they can make a real difference to daily life.

Cholinesterase inhibitors — the mainstay

Rivastigmine is the only medicine FDA-approved specifically for Parkinson's disease dementia. It boosts the brain chemical acetylcholine and, in the pivotal EXPRESS trial, modestly improved thinking, attention, and daily function and reduced hallucinations. It comes as a capsule or a skin patch and is started low and increased slowly to limit side effects (mainly nausea, vomiting, and sometimes worsened tremor or slowed heart rate). Donepezil is a related drug often used off-label with similar benefit. The benefit is modest but real, and many families notice improved alertness and fewer hallucinations.

A realistic note on expectations: cholinesterase inhibitors do not work for everyone, and even when they help, the benefit is usually a modest improvement or a slowing of decline rather than a return to normal. Families often notice the difference most in attention, engagement, and fewer or less troubling hallucinations rather than in memory. It can take several weeks at an adequate dose to judge the effect, so patience and a planned check-in help. If side effects are a problem, switching from capsules to the patch (or vice versa), or trying a different cholinesterase inhibitor, is reasonable. The decision to continue is based on whether you and the care team see meaningful benefit that outweighs any side effects.

Memantine

Memantine works differently (on a system called NMDA) and is sometimes added in moderate-to-advanced disease. The evidence in PDD is more limited than for cholinesterase inhibitors, but it is generally well tolerated and may help some people; it is used off-label for PDD. It is sometimes combined with a cholinesterase inhibitor in later stages, as the two work by different mechanisms. As with all medicines in PDD, the goal is the smallest effective regimen that helps, regularly reviewed — adding drugs without clear benefit only increases side-effect risk. If a medicine is not helping after a fair trial, it is reasonable to stop it; this kind of thoughtful “deprescribing” is as much a part of good care as starting treatments.

Treating hallucinations and delusions safely

Hallucinations and delusions are common and can be distressing. The approach, in order, is usually:

Look for and treat triggers — infection, dehydration, poor sleep, and especially medications.
Simplify medicines — reduce or stop anticholinergics and trim Parkinson's medications most likely to cause hallucinations (in careful balance with movement needs).
Optimize the cholinesterase inhibitor, which itself can reduce hallucinations.
If a specific anti-psychosis medicine is needed, use only the safer options — pimavanserin (FDA-approved for Parkinson's disease psychosis), or cautious low-dose quetiapine or clozapine (clozapine requires regular blood-count monitoring).

It is worth emphasizing that many hallucinations in PDD do not need a new drug at all. If they are mild and the person is not frightened or endangered, the safest course is often reassurance, good lighting, treating any trigger, and reviewing the medication list — not adding a medicine. Medication for psychosis is reserved for hallucinations or delusions that are distressing, frightening, or unsafe. When it is needed, the choice and dose are made carefully by a clinician who knows about Lewy body sensitivity, and the response is monitored closely. Delusions (for example, false beliefs that a spouse is an impostor or that people are stealing) can be particularly distressing and also follow this same careful, step-by-step approach.

Critical safety warning. People with Lewy body conditions, including PDD, can have severe, sometimes life-threatening reactions to antipsychotic drugs (called neuroleptic sensitivity). Avoid haloperidol and other older antipsychotics, and most newer ones (risperidone, olanzapine, aripiprazole). Also avoid the anti-nausea drugs metoclopramide and prochlorperazine, which block dopamine. Make sure every clinician, hospital, and pharmacy knows the diagnosis.

Understanding the medication-safety logic

It helps to understand why the medication rules in PDD are so strict. Lewy body conditions involve a fragile dopamine system and unusual sensitivity to drugs that block dopamine. Antipsychotics that block dopamine can trigger a severe reaction — sudden stiffness, confusion, fever, and dangerous changes in blood pressure and heart rate — that can be life-threatening. The same goes for certain anti-nausea medicines (metoclopramide, prochlorperazine) that block dopamine. This is why doctors reach first for non-drug steps and for the safer options (pimavanserin, low-dose quetiapine, or clozapine), and why the diagnosis must travel with the person to every clinician, hospital, and pharmacy. If you are ever in an emergency room, say clearly: “This person has a Lewy body / Parkinson's dementia condition and cannot have standard antipsychotics or metoclopramide.”

Non-motor symptoms

Treating the “other” symptoms often improves daily life as much as cognitive medicines:

REM sleep behavior disorder (acting out dreams, which can injure the person or bed partner) — managed with bedroom safety measures and medicines such as melatonin or, cautiously, clonazepam.
Orthostatic hypotension (dizziness or faints on standing) — treated with fluids, salt, slow position changes, compression, and sometimes medication.
Depression and anxiety — common and treatable; certain antidepressants are preferred and others avoided.
Daytime sleepiness, insomnia, and constipation — all common and manageable.

These symptoms deserve real attention because they often affect daily life as much as the cognitive changes. Acting out dreams (REM sleep behavior disorder) can injure the person or a bed partner, so bedroom safety — a low bed, padded surroundings, and sometimes a separate sleeping arrangement — matters alongside medication. Dizziness on standing from low blood pressure raises fall risk and can itself cloud thinking; simple measures (rising slowly, more fluids and salt if appropriate, compression stockings, reviewing blood-pressure medicines) help, and medication is available when needed. Depression and anxiety are common, under-recognized, and treatable — and treating them can improve thinking, sleep, and engagement. Poor sleep and constipation both worsen confusion, so they are not minor issues. The key message: report these symptoms, because nearly all of them can be improved, and improving them lifts quality of life for the whole household.

What to expect from rivastigmine

Rivastigmine is started at a low dose and increased slowly over weeks — this gradual approach limits the most common side effects (nausea, vomiting, loss of appetite, and sometimes a temporary increase in tremor). The skin patch can be gentler on the stomach than capsules for some people. Benefits, when they occur, are usually modest and develop over weeks: families often describe a person who is a bit more alert, more engaged, or less troubled by hallucinations. It will not restore lost abilities or stop the illness, and not everyone responds — but because it is the one approved option and can genuinely help, it is usually worth a well-monitored trial. Tell your doctor about any slow heartbeat, fainting, or significant stomach upset, and never stop it abruptly without guidance.

Medication Management in PDD: Timing, Balance, and Practical Tips

Managing medications in PDD requires balancing two competing needs: enough levodopa to control Parkinson's motor symptoms, but not so much that hallucinations or confusion worsen. This balance is individualized and may need adjustment over time as the disease progresses.

Levodopa (usually given as carbidopa-levodopa/Sinemet) is the most effective treatment for Parkinson's motor symptoms. In PDD, that goal has to be balanced against the cognitive effects of dopamine stimulation. Some PDD patients find that higher levodopa doses worsen hallucinations, confusion, or impulsive behavior — this is called dopaminergic psychosis. However, under-treating the motor symptoms leads to rigidity, freezing, falls, and reduced mobility.

Practical points about levodopa in PDD:

Timing matters: Levodopa works best when taken 30–60 minutes before meals or 1–2 hours after meals, because protein in food competes with levodopa for absorption. Consistent timing improves motor predictability
Protein redistribution diet: Some people benefit from eating most of their daily protein at the evening meal, keeping daytime meals lower in protein to maximize levodopa absorption during active hours
"On" and "off" states: As PDD and Parkinson's progress, the effect of each levodopa dose becomes shorter and less predictable. Your neurologist can add a long-acting formulation or other Parkinson's medications to smooth out these fluctuations
Do not stop levodopa suddenly without neurologist guidance. Abrupt discontinuation can cause a severe withdrawal-like syndrome with fever, rigidity, and serious complications

Several drug classes require special caution or should be avoided in PDD because of the risk of severe motor worsening, cognitive worsening, or life-threatening reactions:

Traditional antipsychotics (AVOID): Haloperidol, olanzapine, risperidone, and similar dopamine-blocking antipsychotics can cause severe and sometimes irreversible worsening of Parkinson's motor symptoms in people with Lewy body pathology. This neuroleptic sensitivity reaction can be life-threatening. A medical ID bracelet indicating "Lewy body / PDD — avoid antipsychotics" is strongly recommended
Anticholinergic medications (CAUTION): Diphenhydramine (Benadryl), trihexyphenidyl, benztropine, oxybutynin, and many other medications with anticholinergic properties can significantly worsen memory and cognition in PDD. Avoid unless specifically prescribed by the neurologist who knows the full medication list
Sedating medications (CAUTION): Benzodiazepines (lorazepam, diazepam, clonazepam), sleep aids (zolpidem/Ambien), and sedating antihistamines can cause excessive sedation, increased fall risk, and worsening confusion. Use only as specifically directed by the neurologist
Dopamine-blocking antiemetics (AVOID without neurology input): Metoclopramide (Reglan), prochlorperazine (Compazine), and promethazine block dopamine and can severely worsen Parkinson's motor symptoms. For nausea in PDD, ondansetron (Zofran) is generally preferred

Use a pill organizer or automated dispenser. Missing a Parkinson's medication dose because the person forgot they already took it (or forgot to take it) is a significant risk as PDD progresses. Pre-filled weekly pill organizers, or automated pill dispensers with timed alarms, reduce errors significantly
Track who is giving medications. In households with multiple caregivers or family members, it is easy to accidentally double-dose. Assign one person to manage medications, or use a log that notes each dose given
Rivastigmine patch rotation: The rivastigmine patch should be applied to a different skin site each day. Keep a simple rotation chart. Apply the patch at the same time each day. Remove the old patch before applying a new one — failure to remove the previous patch risks double-dosing, causing severe nausea
Bring a complete medication list to every appointment — including over-the-counter medications, vitamins, and supplements. Drug interactions are common in PDD, and any prescriber outside the neurology team should be aware of the full list before adding new medications

Managing fluctuations

The swings in alertness and clarity that characterize PDD are part of the illness, not a behavior to correct. Practical responses help: schedule demanding or important activities (appointments, decisions, family conversations) during the person's typically clearer times; keep routines predictable; ensure good sleep, hydration, and light exposure during the day; and treat anything that disrupts sleep. If fluctuations suddenly worsen or become severe, look for a reversible trigger (infection, dehydration, a new medicine) and seek a medical review rather than assuming the disease has simply advanced.

Non-Drug Strategies That Genuinely Help in PDD

Medication is the most visible part of PDD treatment, but non-pharmacological strategies provide meaningful benefit that medications alone cannot. This is not an area of "soft" evidence — multiple randomized controlled trials have demonstrated that exercise, cognitive stimulation, and caregiver training produce real, measurable improvements in PDD outcomes. These approaches should be integrated into every PDD care plan, not added as an afterthought if medications fail.

Regular physical exercise is the single intervention with the most consistent evidence for slowing functional decline in Parkinson’s disease, and emerging evidence supports this in PDD specifically. Exercise affects multiple PDD biology targets simultaneously: it increases brain-derived neurotrophic factor (BDNF, a growth factor that supports neuron health), improves cerebral blood flow, reduces neuroinflammation, and improves sleep quality. Practically, it also reduces fall risk by maintaining muscle strength and balance.

What type of exercise?

LSVT BIG: A physical therapy program specifically developed for Parkinson’s disease that uses high-amplitude, large-movement exercises to counteract the characteristic small, shuffling movements of PD. Shown to improve motor function and gait speed. Sessions are conducted by a certified LSVT BIG physical therapist, typically 16 sessions over 4 weeks, followed by home practice.
Aerobic exercise: Walking, cycling, swimming, or treadmill at moderate intensity (able to hold a short conversation) for 30 minutes at least 3 times per week. Produces both motor and cognitive benefits. Safety: always with supervision or at minimum a well-fitted walking aid for people with moderate PDD given fall risk.
Balance and strength training: Tai chi, standing balance exercises, resistance band training. Reduces fall frequency — arguably the most important outcome in moderate PDD. Referral to a physical therapist familiar with Parkinson’s disease for a home exercise program design is strongly recommended.
Dance: Tango and other partnered dance programs have been studied specifically in Parkinson’s disease with consistent motor and social benefit findings. Dance Rock Steady (rockysteadyboxing.org has a directory of PD-adapted programs) and Dancing With Parkinson’s are community programs in many cities.

Safety note: Exercise in PDD must be carefully supervised, especially for people with moderate impairment. Contact the PDD neurologist before starting a new exercise program to identify any cardiac or orthopedic contraindications and discuss medication timing (ideally exercise during the motor "on" period).

Cognitive stimulation therapy (CST) — structured group or individual sessions that engage the person in thinking, reminiscence, and social interaction — has strong RCT evidence in Alzheimer’s disease and is being increasingly applied in PDD and DLB. Even without a formal CST program, the principle applies: regular mentally engaging activity is associated with slower cognitive decline.

Practical ways to provide cognitive stimulation in PDD:

Reading aloud together (even reading to someone who cannot read independently anymore provides stimulation)
Reminiscence activities: looking at family photo albums, listening to music from the person’s young adulthood, watching old films from their youth
Simple puzzles adapted to current ability (crosswords adapted, picture puzzles, word-search books)
Gardening (raised-bed gardening is accessible for people with limited mobility)
Cooking simple familiar recipes with assistance — familiar procedural memory often remains intact longer than declarative memory
Artwork, music, or craft-based activities with family members or in adult day programs

Important: match the activity difficulty to the person’s current cognitive level. Activities that are too difficult cause frustration and withdrawal; those calibrated to the person’s current ability produce enjoyment, engagement, and a sense of accomplishment. A good occupational therapist can assess the person and recommend appropriate activities.

Non-drug approaches

Structured routines, good lighting, reducing clutter and noise, exercise and physical therapy, occupational therapy for daily tasks, and speech therapy for communication and swallowing all help. Treating hearing and vision problems improves thinking. These approaches carry no drug risk and should be part of every care plan.

It is worth being concrete about why these help so much. Because attention and visual processing are impaired, a cluttered or dim environment increases confusion and hallucinations — so simplifying surroundings and improving lighting can visibly reduce symptoms. Because the system is fragile, regular sleep, hydration, movement, and meals stabilize day-to-day functioning. Physical therapy reduces falls; occupational therapy preserves independence in dressing, bathing, and eating; speech therapy protects communication and safe swallowing. Exercise has broad benefits for mood, sleep, mobility, and possibly cognition. None of these carry medication risk, and together they often do more for daily quality of life than any single drug. They should be revisited as needs change rather than offered only once.

Questions to ask your doctor

Should we start (or adjust) rivastigmine, and what benefit and side effects should we expect?
Are any of my current medicines worsening thinking, and can they be reduced?
If hallucinations are a problem, what is the safe step-by-step plan?
What is the complete list of medicines I must never be given?
Which non-motor symptoms should we be treating?

Advanced Disease & Clinical Trials

As PDD advances, the focus shifts toward comfort, safety, function, and supporting caregivers — and, for those interested, clinical trials offer access to investigational approaches.

A note on palliative care

Palliative care is one of the most misunderstood and most helpful services in serious illness. It is specialized support focused on comfort, symptom relief, and quality of life, and it can be provided alongside all other treatment — it is not the same as hospice and does not mean giving up. A palliative-care team can help manage difficult symptoms (pain, agitation, sleep, distressing hallucinations), support difficult decisions, coordinate care, and support the family. Asking for a palliative-care referral is a sign of good, proactive care, and earlier involvement generally leads to better symptom control and less crisis-driven treatment. Hospice, a specific form of comfort-focused care for the last phase of life, becomes appropriate later and brings additional support at home.

Palliative Care and Comfort-Focused Care in PDD

Palliative care is specialized medical care focused on providing relief from pain, symptoms, and the stress of serious illness. In PDD, palliative care is not just for the very final stage — it is appropriate at any point when symptom burden is high or quality of life goals need to be clarified. Involving a palliative care specialist early in PDD often improves both quality of life and reduces unnecessary interventions near the end of life.

A common misunderstanding is that palliative care means "giving up." In fact, palliative care can be provided alongside any treatment, at any stage. It is not the same as hospice, which is specifically for people who are no longer pursuing curative treatment and have a life expectancy of 6 months or less. Palliative care in PDD includes:

Expert symptom management for pain, sleep disturbance, depression, anxiety, and challenging behavioral symptoms
Clarifying what matters most to the person with PDD and their family — their values, goals, and preferences for care
Helping families navigate difficult decisions about hospitalizations, surgery, feeding tubes, and resuscitation
Reducing unnecessary tests and treatments that add burden without adding quality to life
Supporting the family and caregiver (including their grief and mental health)
Coordinating care across the many providers involved in PDD

Palliative care teams typically include physicians, nurses, social workers, and chaplains, and are distinct from the neurology team. Referral to palliative care in PDD is appropriate when:

Symptom burden is high and the neurology and primary care teams feel additional expertise would help
The family is having difficulty with goals of care discussions or advance care planning
Caregiver distress is severe
The person is entering the moderate-to-severe stage of PDD

Hospice is appropriate when the focus of care shifts entirely to comfort, quality of life, and time with loved ones, and when a physician certifies that if the disease follows its expected course, life expectancy is six months or less. In PDD, signs that hospice may be approaching include:

Inability to walk even with assistance (complete motor dependence)
Complete dependence for all activities of daily living including eating and hygiene
Inability to recognize family members or speak meaningfully
Recurrent aspiration pneumonia despite modified diet and positioning
Significant weight loss (>10% in 6 months) despite nutritional support
Inability to swallow safely, with the family having declined a feeding tube after informed discussion

Hospice in PDD is typically provided at home (the most common setting) or in a nursing facility. Families often report that their biggest regret is not calling hospice sooner. Hospice teams bring expertise in pain management, secretion control (to reduce the distressing "death rattle" from retained secretions), anxiety treatment, and family support that most families cannot access on their own.

In Utah, contact the Utah Hospice and Palliative Care Organization (utahhospice.org) for a directory of hospice providers. Most hospice services are covered in full by Medicare Part A for patients who qualify.

Managing advanced disease

In more advanced PDD, priorities include preventing falls, managing swallowing difficulty and the risk of aspiration (pneumonia from food or liquid going into the lungs), maintaining nutrition, treating pain that the person may not be able to describe, and continuing to avoid dangerous medications. Many families benefit from palliative care — an added layer of support focused on comfort and quality of life that can be provided alongside ongoing treatment — and, when appropriate, hospice. Conversations about goals of care and advance planning are easier earlier, while the person can take part.

As mobility declines, attention turns to comfort, skin care, and preventing the complications of immobility; as communication declines, the focus shifts to nonverbal connection and to interpreting needs behind behavior. Decisions about feeding (including whether feeding tubes help, which in advanced dementia they generally do not), hospitalization, and the intensity of treatment are deeply personal and best guided by the person's previously expressed wishes. Many families find that defining what matters most — comfort, being at home, dignity — clarifies these choices when they arise, and that revisiting them over time, rather than deciding everything at once, fits how the illness unfolds.

Safety Considerations in PDD: When to Act Without Waiting

Serious warning signs requiring same-day or emergency evaluation

Sudden severe worsening of cognition or consciousness level — if a person with PDD suddenly becomes much more confused or unresponsive over hours, this is not just disease progression. Infection (especially urinary tract infection or pneumonia), medication error, dehydration, or stroke must be ruled out. Seek same-day medical evaluation.
Fever above 38°C (100.4°F) in a patient on rivastigmine, pimavanserin, or levodopa. Fever can precipitate serious complications including worsening delirium and in rare cases a syndrome resembling neuroleptic malignant syndrome if antidopaminergic medications were recently started or Parkinson's medications were recently stopped.
New inability to swallow (complete refusal to eat/drink or severe choking with all textures) — requires speech-language pathology evaluation urgently to avoid aspiration pneumonia.
Sudden onset of paranoid delusions with agitation where the person becomes a danger to themselves or others — requires emergency evaluation to rule out treatable causes (delirium) before attributing to PDD psychosis.
Fall with head injury in a person with PDD, even if they seem fine afterward. People on anticoagulants or with severe tremor or freezing should be evaluated for intracranial bleeding after any head impact, given the very high fall frequency in this population.

Key medication safety reminders for PDD

Never stop levodopa/carbidopa suddenly — abrupt withdrawal can cause a medical emergency
Never give traditional antipsychotics (haloperidol, olanzapine, risperidone) — neuroleptic sensitivity in Lewy body disease can be life-threatening. Alert all emergency providers.
Acetaminophen (Tylenol) for pain is safe at standard doses. NSAIDs (ibuprofen, naproxen) should be used with caution given fall risk and renal status. Opioids require careful monitoring.
UTI treatment: UTIs in PDD cause severe, rapid worsening of confusion (delirium) that can be mistaken for disease progression. Prompt treatment and maintaining hydration helps resolve the delirium, but recovery of baseline function can take days to weeks after the infection clears. Prevent UTIs with adequate hydration and good hygiene practice.

Safety in advanced disease

Several specific risks deserve attention as PDD advances. Falls become more likely as movement, balance, blood pressure, and attention all interact; a home-safety review, physical therapy, appropriate footwear, removing hazards, and treating orthostatic dizziness all help. Swallowing difficulty can lead to choking and to aspiration pneumonia (when food or liquid enters the lungs); a speech-language pathologist can assess swallowing and recommend textures, positioning, and techniques, and families should learn the signs of aspiration (coughing with meals, wet voice, recurrent chest infections). Nutrition and hydration need monitoring, since appetite and the ability to self-feed decline. Pain may be hard for the person to express and can show up as agitation; look for it actively. And throughout, the medication-safety rules still apply — the risk of a dangerous antipsychotic being given is actually highest during hospital stays and emergencies, so keep the “avoid” list visible and speak up.

Emotional and relationship care

Advancing dementia is a series of losses for everyone involved, and grief, guilt, and exhaustion are normal. The relationship can still hold meaning through presence, touch, familiar music, and shared routines even when conversation becomes hard. Many families find that shifting the goal — from “fixing” to “comforting and connecting” — relieves pressure. Counseling, spiritual support, and peer groups help carry the emotional weight, and they are for the caregiver as much as the patient.

Understanding Clinical Trials in PDD and How to Find Them

Parkinson's disease dementia is an active area of research. Multiple investigational agents are in clinical trials as of 2024–2025, with several in late-stage development. Here is what every family should know about research participation.

The main investigational directions for PDD as of 2024–2025 include:

Alpha-synuclein targeting: Agents designed to reduce, neutralize, or clear the abnormal alpha-synuclein that forms Lewy bodies are the most prominent direction in Parkinson's-related research. Results in Parkinson's disease trials have been mixed to date; PDD-specific alpha-synuclein trials are ongoing. This is the most promising mechanistic direction but is still in early-to-mid clinical development.
Cholinergic system enhancement: Beyond the existing ChEIs (rivastigmine, donepezil), researchers are exploring more targeted cholinergic approaches, including nicotinic receptor agonists and other mechanisms that specifically address the cholinergic deficit in PDD (which is more severe than in Alzheimer's disease).
GBA enzyme replacement and chaperone therapy: For the subset of PDD patients with GBA gene variants, therapies designed to restore glucocerebrosidase enzyme activity may slow the disease process specifically in GBA-PDD. Ambroxol (a mucolytic drug repurposed as a GBA chaperone) is in trials for GBA-Parkinson's disease and PDD. Venglustat and other substrate reduction therapies have been tested in clinical trials.
Sigma-1 receptor agonists: Blarcamesine (ANAVEX2-73) targets the sigma-1 receptor, which is involved in cellular stress responses and autophagy. Investigated in DLB and PDD; results from a Phase 2a trial showed modest cognitive signals warranting further study.
Neuroprotective strategies: Exercise (particularly aerobic and forced exercise approaches) is being investigated not only for symptomatic benefit but potentially for disease-modifying effects through neuroplasticity mechanisms. The SPARX3 and similar trials are evaluating high-intensity treadmill exercise in early Parkinson's disease.
Sleep and RBD intervention: Research is examining whether treating REM sleep behavior disorder (before dementia develops) can modify or delay the onset of Lewy body dementia. Clonazepam and melatonin intervention studies in isolated RBD are ongoing.

The primary resource for finding PDD and DLB clinical trials in the United States is ClinicalTrials.gov. Searching for "Parkinson's disease dementia" or "Lewy body dementia" with filters for "Not yet recruiting" or "Recruiting" status will show currently enrolling trials. The Fox Trial Finder at michaeljfox.org is a curated, patient-friendly tool that matches people with Parkinson's disease (including PDD) to relevant trials based on location and characteristics.

What to ask when contacting a trial:

What are the eligibility criteria? (Key exclusions often include severe dementia, certain medication combinations, or cardiac conditions)
How many visits are required and at what locations?
Are travel expenses or caregiver time reimbursed?
What are the risks of the experimental treatment? What is the placebo rate?
What happens if the trial ends early?
Can I continue my current medications during the trial?

Inform your neurologist before joining any clinical trial — trial medications may interact with current Parkinson's drugs, and some trials have medication eligibility requirements. Your neurologist can help evaluate whether a specific trial is appropriate for your situation.

>Clinical trials and the research pipeline

Honestly, most synucleinopathy research enrolls people with Parkinson's disease or dementia with Lewy bodies rather than PDD specifically, and there is not yet a disease-modifying (disease-slowing) therapy. Still, several efforts are relevant:

Blarcamesine (ANAVEX2-73) — an oral investigational drug studied in a Phase 2 trial in Parkinson's disease dementia (NCT03774459) with a longer extension, reported to affect cognition and other measures; further study is needed.
Neflamapimod — studied in dementia with Lewy bodies (the AscenD-LB Phase 2 trial, NCT04001517, and the larger RewinD-LB study, NCT05869669), targeting brain inflammation and cognition.
Ambroxol — a repurposed drug studied as a possible disease-modifying treatment in PDD (NCT02914366); a 2025 randomized trial did not confirm a cognitive benefit, an important honest result.
Broader Parkinson's and Lewy body trials testing alpha-synuclein-targeted and other strategies may become relevant to PDD over time.

An honest framing helps set expectations. Because PDD sits within the broader Lewy body and Parkinson's spectrum, much of the most promising research — including efforts to target alpha-synuclein itself, the protein at the root of the disease — is being tested first in Parkinson's disease or in dementia with Lewy bodies, with the hope that success would extend to PDD. The failure of ambroxol to improve cognition in its 2025 trial is a reminder that promising ideas do not always pan out, which is exactly why rigorous trials matter. The practical takeaway for families: there is no proven disease-slowing treatment today, but the field is active, new diagnostic tools (like the seed amplification assay) are making trials smarter, and staying connected to a specialist center keeps the door open to emerging options.

Thinking about a trial? Trials are carefully monitored and can offer access to new approaches and expert care, but they carry uncertainty and may involve a placebo. Ask what is being tested, the chance of placebo, the visit schedule, the risks, and what happens afterward. Bring any trial you find to your neurologist, and search ClinicalTrials.gov or ask a Parkinson's organization for help matching.

Questions to ask your doctor

What should we plan for as the disease advances, and when is palliative care appropriate?
How do we keep swallowing, nutrition, and falls as safe as possible?
Are there clinical trials I might be eligible for?
Have we documented goals of care and advance directives?

Exercise, Sleep, and Nutrition in PDD

While medications treat specific symptoms of PDD, three lifestyle factors — exercise, sleep quality, and nutrition — have meaningful effects on quality of life and functional ability. These are things families can actively support every day, in addition to medical treatments.

Exercise is the most evidence-supported non-drug intervention in Parkinson's disease. Studies show that regular physical activity preserves motor function longer, reduces fall risk, and may have modest benefits for cognition. While most of the data come from Parkinson's disease (without dementia), the same principles apply in PDD, with appropriate adaptations for cognitive impairment.

What types of exercise help most:

Walking: Even 20–30 minutes of brisk walking 3–5 times per week has measurable benefits on motor function and mood. In early PDD, a consistent walking program is the most practical starting point. As balance deteriorates, walking with a trekking pole or Nordic walking poles provides additional stability without restricting movement as much as a standard cane or walker
Treadmill walking: Supervised treadmill training with or without a harness has the strongest evidence for improving gait speed and reducing fall risk in Parkinson's disease. Many Parkinson's-specialized centers offer supervised treadmill programs
Cycling: Stationary cycling at a forced pace (a cadence faster than the person would choose spontaneously) — pioneered by the "forced exercise" concept after the well-publicized story of a cyclist named Jay Alberding who rode tandem with his brother with Parkinson's disease and showed dramatic motor improvement — is supported by small but compelling studies. It can be done safely on a recumbent stationary bike with a caregiver facilitating the pace
Balance training and tai chi: Programs specifically targeting balance control (standing on one foot, turning, navigating obstacles) and the mind-body coordination of tai chi have been shown to reduce falls in Parkinson's disease. Adapted tai chi programs for cognitive impairment exist and are offered at some senior centers
Dance: Tango-based dance programs have shown benefits for motor function and quality of life in Parkinson's disease. They also address social connection, which is critically important in PDD where isolation is a major risk
Strength/resistance training: 2–3 sessions per week of resistance exercises preserves muscle mass and functional strength. Important as PDD progresses to prevent the sarcopenia that accelerates functional decline

Practical tips for exercise in PDD:

Exercise is MUCH more effective when it is scheduled and structured rather than leaving it to spontaneous activity. Build it into the daily routine like a medication dose
Time exercise during the motor "on" state (roughly 60–90 minutes after a levodopa dose) when movement is easiest and safest
As cognitive impairment increases, the person may not self-motivate to exercise. Caregivers and companions who exercise with the person dramatically improve adherence
Ask the neurologist for a physical therapy referral for a home exercise program assessment at least once a year
LSVT BIG is a specific Parkinson's exercise program (not generic PT) that has RCT evidence. Find LSVT-certified PTs at lsvtglobal.com

Sleep problems affect almost all people with PDD and have a major impact on both the person and the caregiver. The most common sleep problems in PDD include:

REM Sleep Behavior Disorder (RBD): Acting out dreams (see glossary). Bedroom safety is the most important intervention: pad the floor beside the bed, install bed rails that can be padded, remove lamps and nightstands with hard edges, and consider a low platform bed. Low-dose clonazepam (0.25–0.5 mg) or melatonin (3–12 mg) at bedtime are the standard treatments
Insomnia and fragmented sleep: Frequent nighttime awakenings are common, driven by nocturia (frequent nighttime urination), pain from immobility, difficulty turning in bed, and medication wearing-off effects. Addressing the underlying cause is more effective than adding sleep medications. Scheduled repositioning assistance for people who cannot turn independently, bed rails to facilitate turning, and addressing nocturia (timing diuretics, considering medications for overactive bladder) are practical first steps
Excessive daytime sleepiness (EDS): Very common in PDD, driven by poor nighttime sleep, medication side effects (dopamine agonists are particularly sedating), and the disease process itself. EDS increases fall risk significantly. Review all medications with sedating potential. Structured daytime activity and natural light exposure help consolidate the sleep-wake cycle. If EDS persists, ask about a formal sleep study to rule out obstructive sleep apnea (which is more prevalent in Parkinson's disease than in the general population)
Nighttime confusion and "sundowning": Increased confusion in the evening and at night is characteristic of Lewy body dementia. Bright light during the day, consistent bedtime routines, minimal stimulation in the evening, and night lights to reduce disorientation if they wake during the night all help. Avoid caffeine after noon. If behavioral disturbances at night become severe, a neurologist consultation about low-dose quetiapine (used carefully in PDD given antipsychotic sensitivity) or address any treatable pain, urinary urgency, or medication timing issues first

Nutrition becomes increasingly complex in PDD. Weight loss is common and is associated with faster functional decline. Maintaining adequate nutrition requires attention to several factors:

Protein timing relative to levodopa: Protein in food competes with levodopa for absorption in the small intestine. To maximize levodopa effect during active daytime hours, some people benefit from a protein redistribution approach: low-protein breakfast and lunch, with most of the day's protein taken in at the evening meal. Consult a dietitian for individualized guidance.

Swallowing (dysphagia): Swallowing difficulty is nearly universal in moderate-to-advanced PDD. Signs include coughing or choking while eating, a wet or "gurgly" voice after eating, food or liquid coming out of the nose, prolonged meal times (>45 minutes), and unexplained weight loss. A speech-language pathologist can evaluate swallowing function and recommend appropriate diet textures (chopped, minced, or pureed food) and liquid thickening. Aspiration pneumonia — pneumonia caused by inhaling food or liquid — is one of the most common causes of death in advanced Parkinson's-related conditions. Proactive dysphagia management significantly reduces this risk.

Weight management: Unintentional weight loss of >5% of body weight in 3 months should prompt nutritional assessment. In PDD, causes include reduced appetite from depression or loss of smell (anosmia), swallowing difficulties, forgetting to eat, and increased energy expenditure from motor fluctuations. Oral nutritional supplements (Ensure, Boost, or similar) between meals can provide needed calories without displacing meals. A registered dietitian referral is appropriate when weight loss is identified.

Constipation and hydration: Constipation is nearly universal in PDD due to autonomic dysfunction. Adequate fluid intake (at least 6–8 glasses per day unless restricted by heart or kidney conditions) and dietary fiber are important, though usually not sufficient alone. Ask the neurologist or primary care physician about a scheduled osmotic laxative (like polyethylene glycol/MiraLAX) as a daily intervention if dietary measures are insufficient.

Living Well & Support

PDD affects the whole family. Practical strategies, the right resources, and caregiver support make daily life better and safer.

Practical Daily Function Strategies in PDD

As PDD progresses, maintaining daily function and independence requires creative strategies that work with the disease rather than against it. This section covers practical approaches developed from occupational therapy evidence and the collective experience of PDD families.

People with PDD generally function better with a predictable, structured daily routine. Unpredictable changes cause more confusion and distress than familiar activities, even repetitive ones. Building a consistent daily structure helps the person with PDD anticipate what comes next, reduces agitation, and makes caregiving more sustainable.

Effective morning routine principles:

Rise at the same time each day — consistent sleep-wake timing helps regulate the sleep-wake cycle and may improve nighttime sleep quality
Take Parkinson's medications first thing in the morning (before breakfast if possible) to allow the levodopa to take effect during the most active part of the morning routine. The "morning off" period before medications kick in is one of the most dangerous times for falls
Structure morning activities from easiest to most cognitively demanding — basic self-care (teeth, face, dressing) while cognition is still warming up, more cognitively demanding activities (reading, conversation, decision-making) later in the morning after the levodopa has taken full effect
Build in enough time — rushing increases anxiety and fall risk. If a task took 20 minutes last year, it may take 45 minutes now. Factor this into the schedule rather than trying to maintain previous timeframes
Keep mornings calm and low-stimulation — loud TV, complex conversation, or multiple concurrent demands during the morning transition are common sources of confusion and agitation in PDD

Scheduling activities by cognitive state: Many families learn to identify the 2–4 hour window when the person with PDD is most cognitively alert and physically mobile (usually mid-morning, 1–2 hours after morning medications). Scheduling the most important activities — medical appointments, meaningful social interactions, bathing, exercise — during this window maximizes success and minimizes distress.

Maintaining as much independence as possible in activities of daily living (ADLs) preserves dignity and reduces caregiver burden. The goal is not to do things for the person with PDD, but to set up the environment and tasks so they can do as much as possible themselves safely. Occupational therapy (OT) is the specialty that focuses specifically on this, and an OT home visit is one of the highest-value referrals in early-to-moderate PDD.

Dressing:

Replace buttons and zippers with Velcro closures, magnetic snaps, or elastic waistbands
Lay clothes out in the order they will be put on the night before
Sit to dress whenever possible — reduces fall risk dramatically
Slip-on shoes or elastic laces eliminate the hazard of untied laces while maintaining independence

Bathing:

Walk-in showers with a shower seat and handheld showerhead are dramatically safer than tub baths in PDD. If a tub conversion is not possible, a bath transfer bench allows safe tub bathing without needing to step over the high tub wall
Non-slip mats inside and outside the shower are essential
A grab bar at the entry point of the shower and a second bar inside are minimum safety additions
As motor function declines, scheduling bathing during the medication "on" state improves safety significantly

Eating and kitchen safety:

Adapted utensils (weighted utensils for tremor, built-up handle grips, angled spoons) improve eating independence and reduce meal-time stress
A plate guard or lipped plate prevents food from sliding off
Cups with weighted bases or sippy-style cups reduce spills
As swallowing becomes problematic, consult a speech-language pathologist for food texture recommendations before a choking episode or aspiration event occurs
Remove stove access once cooking safely is no longer possible — this is one of the most common home hazard concerns in moderate PDD

The home environment should be modified proactively, before falls occur, because the consequences of falls in PDD are severe (hip fractures, head injuries, hospitalization-related delirium).

High-priority modifications:

Remove trip hazards: Loose rugs, extension cords crossing walkways, low furniture in pathways, thresholds between rooms, and clutter. This is the single most impactful fall prevention modification
Bathroom safety: Grab bars beside the toilet and in the shower (not towel bars, which are not load-bearing — grab bars must be anchored to studs). A raised toilet seat with armrests makes sitting and rising from the toilet much safer
Adequate lighting: Night lights in hallways, bathroom, and bedroom. Automated motion-sensing lights eliminate the need to fumble for switches during nighttime bathroom trips. The person with PDD should never navigate a dark hallway
Stair safety: Both stair handrails solid and anchored; stair lighting adequate; consider a stair gate at the top of stairs for overnight safety if nighttime confusion is present. Single-story living is strongly preferred in moderate-to-advanced PDD
Bed height: The bed should be at a height where the person's feet are flat on the floor when sitting on the edge of the bed, to allow safe rising. Bed rails should be partially raised (not full-length) to assist with turning, with padding on any hard edges
Personal emergency response system (PERS): A wearable button that calls for help if the person falls. Most important for periods when the person is alone at home. Many systems now include fall detection (automatic alert without pressing the button). Medicare Advantage and many Medicaid plans cover PERS; basic monthly costs range from $20–$50/month

Behavioral symptoms — what helps

Beyond hallucinations, PDD can bring apathy (loss of motivation, often mistaken for depression or laziness), anxiety, agitation, and changes in mood or behavior. Non-drug approaches are the foundation and are often more effective and far safer than medication: keep a calm, predictable routine; reduce overstimulation (noise, crowds, too many choices); break tasks into simple steps; use gentle redirection rather than confrontation; and look for unmet needs behind agitation (pain, hunger, needing the bathroom, boredom, fatigue, or overstimulation). Apathy can sometimes improve by structuring engaging, low-pressure activities and treating any depression. When medication is truly needed for severe distress, remember the safety rules — the dangerous antipsychotics are off the table, and the team should choose carefully. Document what triggers and what soothes the person; this practical knowledge is invaluable to everyone involved in care.

Daily strategies

Work with the fluctuations: plan important activities and conversations for the person's best times of day, and don't push during foggy spells.
Respond to hallucinations calmly: if they are not distressing, gentle reassurance and good lighting often help more than arguing; report new or frightening hallucinations to the care team.
Make the home safe: reduce clutter and trip hazards, improve lighting, secure the bedroom for dream-enactment safety, and consider grab bars and removing loose rugs.
Keep a routine and a written, up-to-date medication list — and carry the “medicines to avoid” list everywhere.
Stay active and connected: exercise, physical and occupational therapy, social contact, and treating hearing/vision all support thinking and mood.

A few more practical touches help day to day: post a large-print daily schedule and a clock/calendar in view; lay out clothes and medications in order; use contrasting colors (for example, a dark plate on a light table) to aid visual perception; keep a nightlight and a clear, unobstructed path to the bathroom for nighttime safety; and reduce decisions and choices, which can overwhelm. Build in meaningful, low-pressure activities the person enjoys, and accept that participation will vary with the fluctuations. Carry an up-to-date medication list and the “medicines to avoid” card to every appointment and especially to any emergency visit. These small environmental changes consistently reduce confusion, agitation, and falls.

Caring for someone with PDD is demanding — you are managing fluctuating cognition, hallucinations, movement problems, sleep disruption (including dream-enactment that can be dangerous), and complex medications. Protect yourself and the person you care for: learn the warning signs that need urgent care (sudden confusion, falls, choking, signs of infection), keep the “avoid” medication list with you for every hospital or ER visit, and insist clinicians know about neuroleptic sensitivity. Build in respite and accept help; arrange home safety and, when needed, additional care. Watch for caregiver depression and burnout, which are common and treatable. Support groups — through Parkinson's and Lewy body organizations — connect you with others who understand.

Communicating Effectively With Someone Who Has PDD

Communication changes fundamentally as PDD progresses. The cognitive features of PDD — slowed thinking, attention difficulties, word-finding problems, and fluctuating alertness — combined with Parkinson's disease effects on voice volume (hypophonia) and facial expression (facial masking) create unique communication challenges. Learning to adapt communication style significantly reduces frustration on both sides and maintains connection longer.

Prepare the environment first:

Turn off the television or radio before starting a meaningful conversation — background noise is significantly more disruptive in PDD than for cognitively intact people
Make eye contact and come to their level (sit if they are sitting) before beginning to speak
Use their name to signal that you are speaking to them specifically
Time conversations during the cognitive "on" period — roughly 1–2 hours after morning Parkinson's medications

How to phrase things:

Short, simple sentences. One idea per sentence. Long compound sentences with multiple clauses lose people with PDD mid-sentence.
Ask yes/no questions rather than open-ended questions when a decision needs to be made. "Would you like tea?" works much better than "What would you like to drink?" as PDD progresses
Offer two choices at most for decisions that need input: "Would you like the blue sweater or the red one?" rather than presenting the whole closet
Avoid "Do you remember...?" This question format highlights memory failure and creates shame. Instead, share the memory as a statement: "I was thinking about when we went to Lake Powell together."
Don't finish sentences or correct errors unless the error creates a safety issue. People with PDD need time to process and respond. The natural conversational pause is often 3–5 seconds longer in PDD than usual. Wait.
When they can't find a word, offer options: "Is it something you drink? Something in the kitchen?" rather than either guessing immediately or leaving them struggling alone

Managing Parkinson's voice problems: Hypophonia (very soft voice) makes it difficult to understand what the person is saying. Strategies include: asking the person to speak louder explicitly ("Can you say that again, a little louder?"); reducing ambient noise; speech therapy (LSVT LOUD) to improve voice volume; and family members learning to listen more carefully rather than asking the person to repeat multiple times (which causes frustration and discouragement from attempting conversation).

As verbal communication becomes very difficult in advanced PDD, families often underestimate how much connection is still possible through non-verbal means. Research consistently shows that people with advanced dementia can still:

Respond to and convey emotion through touch, facial expression, tone of voice, and body language
Recognize and respond emotionally to music from earlier in their life, even when they can no longer identify the song or recall the memory
Respond to familiar smells (a partner's perfume, a favorite food) when verbal recognition is absent
Experience comfort and distress, even when they cannot report it verbally

Simple communication techniques that remain effective in advanced PDD:

Hold their hand during difficult care routines — familiar touch is calming even when words are not understood
Play music they loved at age 20–30 (the "reminiscence bump" — music from young adulthood retains emotional power longest in dementia)
Speak in a calm, slow, warm voice even when they appear unresponsive — hearing and emotional processing are often preserved even when response ability is absent
Photo books and familiar objects from earlier in life can spark recognition and connection when abstract verbal conversation cannot

Communicating and connecting

Thinking changes affect communication, but connection remains very possible. Speak in short, simple sentences, one idea at a time; allow extra time for a response; reduce background noise and competing demands; and use a calm, warm tone — emotional connection often outlasts factual memory. Avoid quizzing (“do you remember…?”) and arguing about hallucinations or misperceptions; redirect gently instead. Treating hearing and vision problems makes a real difference. Familiar music, photos, and routines can be grounding and comforting.

Driving and Mobility Independence: Navigating Difficult Transitions

Driving cessation is one of the most emotionally charged transitions in PDD. For many people, driving represents independence, identity, and practical autonomy. Yet driving with PDD becomes increasingly dangerous as cognitive impairment, visuospatial dysfunction, motor fluctuations, and medication effects progress. Addressing this conversation early — before a crisis — is kinder and safer for everyone.

There is no single cognitive score or symptom threshold that defines when driving becomes unsafe — driving fitness is a clinical assessment that considers multiple factors. The following are established red flags that strongly suggest driving should be evaluated or stopped:

MoCA score below 24 (mild dementia range) in combination with Parkinson's motor symptoms substantially increases crash risk. Some guidelines suggest formal driving evaluation for any person with PDD regardless of score
Visual hallucinations that intrude during wakefulness — visual disturbances while driving are an immediate safety concern regardless of insight level
Significant motor fluctuations with unpredictable "off" episodes (sudden onset of stiffness, tremor, or freezing) while driving
Any at-fault accident or near-miss in the preceding 12 months
Getting lost in familiar areas, difficulty finding the way home from places driven to routinely
Excessive daytime sleepiness or documented episodes of falling asleep unexpectedly (which can occur with Parkinson's medications, especially dopamine agonists)
Family or passenger concern about driving safety — family-reported concern has strong predictive validity for actual driving impairment in dementia

Involve the neurologist: Asking the neurologist to raise the driving question (rather than a family member being the "bad guy") often lands better. Many states, including Utah, require or permit physicians to report patients with medical conditions that impair driving ability to the DMV. In Utah, the Driver License Division can receive physician reports and may require a driving evaluation or impose restrictions.

Formal driving evaluation: A certified driving rehabilitation specialist (CDRS) — often an occupational therapist with specialized training — can provide an objective driving evaluation, including both in-office cognitive testing and an on-road driving test. This removes subjectivity from the family dynamic. Recommendations from a CDRS (continue, continue with restrictions, or stop) carry more weight with the person with PDD than family opinion. Find a CDRS through the Association for Driver Rehabilitation Specialists (ADED) at driver-ed.org.

If driving must stop: Transportation alternatives should be identified before driving stops, not after. Options include: family or friend transportation networks (scheduling this in advance is critical); medical transport services (arranged through the PDD person's insurer or Medicaid for medical appointments); ride-share apps (Lyft and Uber have programs for older adults, and some family members manage the app for their relative); community volunteer driver programs; and paratransit services through local transit agencies for people with disabilities.

Driving cessation dramatically increases social isolation and depression risk in older adults, particularly men for whom driving is strongly tied to independence and identity. Planning for this transition is not just a safety matter — it is a wellbeing matter.

Frame driving cessation as a transfer of responsibility ("I need to be your driver now") rather than a loss of privilege
Create a reliable weekly schedule of outings that maintain the person's connection to activities they value
For people who loved to drive as an activity, consider passenger rides specifically for the pleasure of the outing, not just for errands
Watch for worsening depression after driving cessation — this is a high-risk period and should be assessed by the clinical team
Consider involving the person in planning their transportation so they retain some sense of control and agency

Driving and safety

Driving is often one of the hardest topics, because it touches independence so directly. The thinking changes in PDD — slowed reactions, divided-attention difficulty, visuospatial problems, and fluctuations — can make driving unsafe, sometimes before the person recognizes it. Rather than a single confrontation, approach it as an ongoing safety question: ask the clinician for an honest assessment, request a formal on-road driving evaluation when there is doubt, and plan transportation alternatives early (family, rideshare, paratransit, community senior transport). When it is time to stop, framing it around safety for the driver and others, and ensuring mobility is preserved through alternatives, makes the transition less of a loss. Similar care applies to other safety-sensitive activities, firearms in the home, cooking unattended, and managing finances, all of which may need gradual adaptation.

Planning ahead

Because fluctuations mean there are clearer times, it helps to address important planning early, while the person can participate as much as possible. Consider putting in place advance directives, a health-care proxy or power of attorney, and financial and legal arrangements; discuss wishes about future care and where the person would want to be cared for. Practical steps — simplifying finances, setting up bill-pay, organizing documents, and planning transportation as driving becomes unsafe — reduce stress later. Driving safety should be assessed honestly and revisited over time. These conversations are hard but are a gift to the whole family.

Mountain West / Utah

University of Utah Health — Movement Disorders and Cognitive Neurology programs (Salt Lake City): specialist evaluation, treatment, and trials for Parkinson's and related dementias; appointments via University of Utah Health (801-585-7575).
Intermountain Health neurology — services across the Wasatch Front and Intermountain West.
George E. Wahlen VA Medical Center (Salt Lake City) — neurology and geriatric care for veterans.
Local Area Agencies on Aging and Utah caregiver-support programs — respite, day programs, and practical help.

Caregiver self-care and respite

Caring for someone with PDD is a marathon, and the evidence is clear that caregiver health directly affects the person being cared for. Protecting yourself is not selfish — it is part of the care plan. Build in regular respite: adult day programs, in-home help, or short stays let you rest and tend to your own needs. Accept offers of help and be specific about what you need (a meal, a few hours, a ride). Watch for signs of caregiver depression and burnout — persistent exhaustion, hopelessness, irritability, sleep problems, or withdrawing from others — and seek support early; these are common and treatable. Stay connected to your own medical care, friendships, and activities. Support groups, in person or online through the Lewy Body Dementia Association and Parkinson's organizations, connect you with people who truly understand, and many offer care-partner education and one-to-one mentoring.

Caregiver Resilience and Preventing Burnout in PDD

Caregiving for someone with PDD is one of the most demanding caregiving roles in all of medicine. The combination of progressive motor disability (making all physical care increasingly labor-intensive), dementia (requiring 24-hour supervision as the disease advances), behavioral symptoms (hallucinations, paranoia, agitation, nighttime disturbances), and the day-to-day unpredictability of Lewy body fluctuations creates caregiver demands that exceed those of Alzheimer's disease caregiving in many studies. Caregiver burnout is not a sign of weakness or failure — it is a predictable outcome when the demands of caregiving exceed available resources and support.

Burnout does not arrive suddenly; it builds over months. Recognizing the early warning signs allows intervention before a crisis occurs. Warning signs include:

Exhaustion that is not relieved by rest — waking up tired even after sleeping
Feeling isolated — withdrawing from friends, family, and activities you used to enjoy
Feeling hopeless — believing that no matter what you do, nothing will improve
Neglecting your own health — skipping your own doctor appointments, medications, meals, or exercise
Increased irritability, resentment, or anger toward the person you are caring for (followed by guilt)
Physical symptoms: headaches, stomach problems, frequent illness (stress suppresses immune function)
Depression or anxiety symptoms that persist for more than two weeks

If you recognize these warning signs in yourself, treating them is not selfish — it is necessary to sustain the care you provide. Caregiver burnout is the most common reason for premature nursing home placement; addressing it directly keeps more people at home longer.

Build in respite systematically: Respite — planned breaks from caregiving — must be a regular, scheduled part of the care plan, not something that only happens in a crisis. Options include adult day programs (typically 4–8 hours, 2–5 days per week); in-home respite care (a trained aide comes to the home to allow the primary caregiver to leave); overnight respite at a memory care facility; family/friend-based respite rotations; and VA caregiver respite programs for veterans and their caregivers.

Accept help when it is offered: Many caregivers refuse help when it is first offered, often because of a belief that they "should" be able to manage alone, or because accepting help feels like an admission that the situation is serious. Accepting help early, before you need it desperately, is much better for everyone. Specific tasks that can be delegated to helpers: grocery shopping, transportation to appointments, meal preparation, companionship/socialization visits, yard work, or financial bill-paying.

Connect with others who understand: Online and in-person support groups for Lewy Body Dementia (LBDA support group locator at lbda.org) provide a community that understands the specific challenges of PDD — the hallucinations, the fluctuations, the antipsychotic sensitivity, the motor-cognitive dual burden — in a way that generic dementia support groups do not. Many caregivers report that connecting with a community that has the same experience is one of the most powerful supports they find.

Set achievable goals, not perfect ones: PDD will progress. The goal of care is not to stop progression or to deliver perfect care — it is to provide the best quality of life possible for the person with PDD, and to preserve the caregiver's own health and wellbeing enough to continue providing that care. Days when you did not do everything perfectly are not failures; they are normal. What matters is the sustained quality of presence and care over months and years, not perfection on any individual day.

Use your own healthcare team: Caregiver depression is common and treatable. If your primary care physician does not know you are the primary caregiver for someone with PDD, tell them — it is clinically relevant to your own health. Ask about caregiver-specific mental health resources, including brief counseling or medication for depression or anxiety if needed.

Financial and practical assistance

Dementia care has real costs. Ask the care team's social worker about benefits and programs you may qualify for, including help through Medicare and Medicaid, veterans' benefits (the VA offers caregiver support programs), and Area Agencies on Aging, which can connect you to respite, transportation, meal programs, and home-safety resources. Long-term-care planning, including the possibility of memory care, is worth exploring before a crisis forces rushed decisions. Disease-specific organizations often maintain lists of financial-assistance and care-navigation resources.

National organizations

Parkinson's Foundation (parkinson.org) — Helpline 1-800-473-4636 (1-800-4PD-INFO); education and local resources.
Lewy Body Dementia Association (lbda.org) — PDD/DLB-specific information, support groups, and a care-partner network.
American Parkinson Disease Association (apdaparkinson.org) and the Michael J. Fox Foundation (michaeljfox.org) — resources and trial-matching.
Alzheimer's Association (alz.org; 24/7 Helpline 1-800-272-3900) — dementia caregiving support that applies broadly.
ClinicalTrials.gov — searchable trial registry.

Peer Support, Community, and Connecting With Others Affected by PDD

Parkinson’s disease dementia is an isolating condition — for the person diagnosed and for their caregivers. The combination of motor and cognitive symptoms can make social participation increasingly difficult. Yet the research consistently shows that social connection is protective for both brain health and caregiver wellbeing. Actively building and maintaining a support network is not a luxury; it is part of good care.

Support groups serve two populations with different needs: the person living with PDD (especially in earlier stages), and caregivers and family members. Research shows that participation in support groups is associated with lower caregiver burden scores, better problem-solving ability, and reduced isolation. What to expect from different types of groups:

Parkinson’s disease support groups (general): Address motor and non-motor PD symptoms broadly. Useful especially in early PDD. People in earlier stages often connect with others who are managing similar challenges. Find through Parkinson’s Foundation (parkinson.org/find-support) or American Parkinson Disease Association (apdaparkinson.org).
Dementia caregiver support groups: Address cognitive and behavioral challenges that Parkinson’s-specific groups may not fully address. Alzheimer’s Association (alz.org/care/support-groups) offers hundreds of in-person and virtual groups nationally.
Lewy body dementia-specific support groups: Directly address PDD and DLB. The Lewy Body Dementia Association (LBDA; lbda.org) offers a peer support line (1-800-539-9767) and an LBD Caregiver Link matching program connecting caregivers with trained volunteer mentors who have direct LBD caregiving experience.
Online and virtual groups: Many families find virtual groups more accessible once mobility or transportation becomes challenging. Facebook groups for Lewy Body Dementia Caregiver Support and similar communities have large active memberships. Quality varies; prioritize groups moderated by recognized advocacy organizations.
Young-onset PDD groups: For people diagnosed with PD before age 50 who develop PDD, or for younger caregivers, separate peer groups address the distinctive challenges (employment, parenting, financial impact on younger families).

Respite care provides temporary relief for the primary caregiver — ranging from a few hours to several weeks. Chronic caregiver fatigue without respite is associated with depression, physical health decline, and premature placement of the person with PDD in a care facility. Types of respite:

In-home respite (companion aide): A paid aide stays with the person while the caregiver is away. Access through home care agencies (check with insurance; Medicaid waiver programs often fund these). In Utah, the Adult Day Services program and Area Agency on Aging (1-877-424-4640) can connect families with in-home respite providers.
Adult day health programs: The person with PDD attends a structured program several days a week in a supervised setting, providing cognitive stimulation, socialization, and medical oversight while the caregiver works or rests. These programs often have exceptional staff trained in dementia care. Ask the neurologist or social worker for referrals in your area.
Short-stay (overnight) respite: Some skilled nursing facilities and residential care facilities offer short-term respite admissions (typically 1–2 weeks) for planned caregiver vacations, caregiver illness, or family emergencies. Medicaid may fund short-stay respite; check with the care facility directly about eligibility and waitlists.
Family and friend respite: Many caregivers underutilize their social network because they feel others "wouldn’t know what to do." Training family members and trusted friends in basic care routines — with the help of a home health aide who can demonstrate — expands the available respite pool significantly.

Making the most of organizations and online information

The organizations listed here offer far more than pamphlets: helplines staffed by people who understand the disease, care-partner education and mentoring, local support groups, trial-matching services, and practical guidance on benefits and care planning. The Lewy Body Dementia Association is especially valuable because PDD and dementia with Lewy bodies are its specific focus, including the all-important medication-safety information. When researching online, stick to established, non-commercial sources (the organizations here, the National Institute on Aging, and major academic centers), be wary of products promising to cure or reverse dementia, and bring anything you read — especially about new treatments or trials — to your own clinician to check whether it applies to your situation. A trusted clinician plus one or two reputable organizations is usually a better information strategy than wide, anxious searching.

International access

Rivastigmine is approved for Parkinson's disease dementia in the US, EU, UK, Canada, Japan, and Australia; memantine and donepezil are used off-label for PDD in most regions. Pimavanserin is FDA-approved (US) for Parkinson's disease psychosis but is not approved by the European Medicines Agency, so clinicians elsewhere rely more on cautious low-dose quetiapine or clozapine. MIBG cardiac scanning to support diagnosis is used much more in Japan than in the US or Europe. Across all regions, PDD and dementia with Lewy bodies are managed within the same Lewy body disease framework, and the neuroleptic-sensitivity precautions are universal.

If you are outside the United States, the core approach is the same, but specifics differ: rivastigmine is broadly available for PDD, while access to pimavanserin is essentially US-only, so clinicians elsewhere rely more on cautious quetiapine or clozapine for psychosis. Some countries (notably Japan) use the MIBG heart scan more often to support diagnosis. Wherever you are, the universal rules hold: avoid the dangerous antipsychotics and dopamine-blocking anti-nausea drugs, minimize anticholinergic medicines, look hard for reversible causes of sudden decline, and offer cholinesterase-inhibitor therapy and strong caregiver support. Ask your local specialist what is approved and reimbursed where you live, and whether a clinical trial offers access to investigational options.

Planning Ahead: Long-Term Considerations in PDD

PDD is a progressive disease. Planning ahead — before major abilities are lost — allows the person with PDD and their family to make decisions while the person is still able to participate in them. This section covers the most important planning conversations and practical steps to take at each stage.

Legal planning is one of the most important early steps after a PDD diagnosis. The goal is to ensure that the person's wishes are documented while they still have the cognitive capacity to legally execute documents. Waiting too long risks losing the ability to plan independently.

Priority documents (execute within the first 6–12 months of diagnosis):

Durable Power of Attorney (DPOA) for finances: Designates a trusted person to manage financial affairs when the person with PDD can no longer do so. This is different from a standard power of attorney, which becomes invalid if the person becomes incapacitated. A durable POA remains in effect even after incapacity.
Healthcare Power of Attorney / Healthcare Proxy: Designates a person to make medical decisions if the person with PDD cannot. This person should understand the person's values and wishes, and should be someone who can make difficult decisions under pressure.
Living Will / Advance Directive: Documents the person's wishes about life-sustaining treatment (CPR, mechanical ventilation, feeding tubes, IV fluids) in specific scenarios. Utah uses a form called the Advance Health Care Directive. Your neurologist or hospital social worker can provide the form.
POLST (Physician Orders for Life-Sustaining Treatment): A medical order (not just a directive) that translates the person's wishes into specific, actionable instructions for emergency medical personnel. This is especially important as PDD progresses, because EMTs and emergency physicians who do not know the patient will default to aggressive resuscitation without a POLST. In Utah, this is called a POLST form and must be signed by a physician.
Will and trust review: Review existing wills and trusts with an elder law attorney to ensure they still reflect the person's wishes and are structured appropriately for a family navigating a progressive illness.

Most families want to care for someone with PDD at home for as long as possible. Planning for the stages in advance allows better decision-making when the time comes, rather than crisis-driven placement decisions.

Early-to-moderate PDD (typically years 1–4 of dementia): Most people can remain at home with a caregiver (spouse, adult child, or combination). Home safety modifications (grab bars, stair rails, removing trip hazards, nightlights, door alarms) significantly reduce fall and wandering risk. Adult day programs provide structured socialization and cognitive stimulation while giving caregivers a break. Home health aides can assist with bathing, medication management, and transportation.

Moderate PDD (typically years 3–6 of dementia): Full-time care at home becomes a major undertaking. For families without a full-time caregiver, memory care residential facilities or assisted living with memory care units may be appropriate. When evaluating facilities, ask specifically about their experience with Parkinson's disease dementia and Lewy body dementia — as distinct from Alzheimer's disease — because the behavioral profile (hallucinations, severe motor disability, falls) is substantially different.

Advanced PDD: People in advanced PDD are often immobile and fully dependent for all activities of daily living, with significant swallowing difficulty. Skilled nursing facilities or hospice at home are typically the appropriate settings. The key decisions at this stage are around the goals of care: pursuing hospitalizations and resuscitation vs. prioritizing comfort and quality of remaining time.

Medicare Part D (prescription drug coverage): Covers most medications used in PDD (rivastigmine, memantine, pimavanserin). Extra Help / Low Income Subsidy (LIS) program reduces Part D costs for low-income beneficiaries. Apply through Social Security Administration at ssa.gov.
Medicaid Waiver Programs (Utah): Utah's DSPD (Division of Services for People with Disabilities) and DAAS (Division of Aging and Adult Services) offer home and community-based waiver programs that pay for home health aides, adult day programs, and respite care for low-income individuals. Waitlists exist; apply early.
Veterans benefits: Veterans with PDD may qualify for Aid & Attendance (a pension supplement for veterans who need help with daily activities), the Caregiver Support Program, and community-based care programs through the VA. The VA Wahlen Medical Center in Salt Lake City has a geriatrics and extended care service that handles these applications.
Social Security Disability Insurance (SSDI): If the person with PDD is under 65 and is unable to work due to PDD and Parkinson's, they may qualify for SSDI. Parkinson's disease with dementia may qualify for expedited processing under the SSA Compassionate Allowances list.
Pharmaceutical patient assistance programs: Acadia Pharmaceuticals (maker of Nuplazid/pimavanserin), Novartis (Exelon/rivastigmine), and Forest Labs (Namenda/memantine) all have patient assistance programs for people who cannot afford medications. Ask your neurologist's office for assistance with enrollment, or contact the manufacturer directly.

Why Certain Treatments Don’t Work in PDD (And Why That Matters)

Understanding what hasn’t worked in PDD is clinically and practically important. It protects people with PDD from being given treatments developed for other dementias that do not help and may harm, and it sets realistic expectations about the current limits of what medicine can offer.

Most people have heard of new Alzheimer’s treatments such as lecanemab (Leqembi) and donanemab, which remove amyloid plaques from the brain. These drugs have shown benefit in early Alzheimer’s disease. However, they do not work in PDD or DLB because the primary pathology in PDD is alpha-synuclein (Lewy bodies), not amyloid. While some people with PDD also have co-occurring amyloid, removing amyloid alone does not address the Lewy body component. These drugs have not been studied in PDD and are not currently indicated for it.

Similarly, anti-tau therapies being developed for Alzheimer’s disease are unlikely to be the right target for PDD, which has a different primary molecular pathology. Families who read about Alzheimer’s advances should understand that those trials typically explicitly excluded Lewy body disease.

Several medication classes that are standard treatments for behavioral symptoms in other dementias (Alzheimer’s, vascular dementia) are specifically dangerous in PDD due to Lewy body neuroleptic sensitivity. This has caused real harm historically, when the Lewy body nature of PDD was not yet widely recognized.

Typical antipsychotics (haloperidol, perphenazine): Can cause sudden, severe, life-threatening reactions in Lewy body disease including rigidity, respiratory failure, and neuroleptic malignant syndrome-like states. These should never be used in PDD.
Most atypical antipsychotics (risperidone, olanzapine): Even lower-risk atypical antipsychotics used in Alzheimer’s disease carry significant risks in PDD. Motor worsening, excessive sedation, and paradoxical worsening of psychosis have all been reported.
Metoclopramide (Reglan) for nausea: A dopamine blocker commonly given for nausea or gastroparesis. Causes acute and sometimes irreversible motor worsening in PD and PDD. Safer antiemetic alternatives exist (ondansetron, domperidone where available).
Benzodiazepines for sleep or agitation: While they are sedating, benzodiazepines paradoxically worsen cognition and increase fall risk in PDD without consistently improving behavior. They also suppress REM sleep (already often disrupted in PDD). Short-term use in specific situations may be acceptable; long-term use for behavioral management is not recommended.

Many families explore supplements and complementary approaches for PDD. While some carry low risk, none has been proven to slow or halt PDD progression in clinical trials. The most common ones families ask about:

Omega-3 fatty acids (fish oil): Theoretically anti-inflammatory; no RCT evidence for benefit in PDD cognitive decline specifically. Safe at standard doses. Not a substitute for other proven strategies.
Coconut oil / MCT oil: Widely promoted online as a dementia treatment based on a single anecdotal case report (not a clinical trial). No controlled trial evidence in PDD or any other dementia type.
High-dose vitamin E: Studied in Alzheimer’s disease (negative result). Not studied adequately in PDD and high-dose vitamin E carries cardiovascular risk at doses >400 IU/day.
Herbal supplements: Many interact with PDD medications. Ginkgo biloba interacts with anticoagulants and has produced inconsistent results in dementia trials. St. John’s Wort is a strong drug interaction risk (CYP3A4 inducer) that can reduce levels of many medications used in PDD. Always disclose supplements to the neurology team.

What has not worked

Being clear about what does not help prevents wasted effort and risk. Ambroxol, a repurposed drug hoped to be disease-modifying, did not improve cognition in a 2025 randomized PDD trial. Antipsychotics for behavior are not only unhelpful for the dementia itself but are dangerous in Lewy body disease and carry warnings about increased death in older people with dementia. Anticholinergic drugs (some older Parkinson's, bladder, sleep, and allergy medicines) worsen thinking and should be minimized. There is, as yet, no proven disease-slowing therapy.

PDD: Parkinson's disease dementia — dementia developing in established Parkinson's disease.
DLB: dementia with Lewy bodies — closely related; distinguished by timing (the 1-year rule).
Lewy body / alpha-synuclein: the protein clumps underlying both conditions.
Cholinesterase inhibitor: medicine (rivastigmine, donepezil) that boosts acetylcholine to aid thinking.
Neuroleptic sensitivity: dangerous reactions to antipsychotic drugs in Lewy body disease.
Fluctuations: swings in alertness and thinking over hours or days.
RBD (REM sleep behavior disorder): acting out dreams during sleep.
Orthostatic hypotension: blood-pressure drop on standing, causing dizziness.
Anticholinergic: drugs that block acetylcholine and worsen thinking.
SAA (seed amplification assay): a newer test detecting misfolded alpha-synuclein.

Genetics, Family Risk, and What to Tell Adult Children

PDD and the broader Lewy body disease spectrum are not purely genetic conditions, but genetic factors play a meaningful role for some families. Understanding the hereditary landscape helps adult children of people with PDD make informed decisions about genetic testing and risk reduction.

What is the familial risk? First-degree relatives (children, siblings) of people with Parkinson’s disease dementia or DLB have approximately 2–3 times the population risk of developing a Lewy body disease. The overall population lifetime risk is roughly 1–2%; first-degree relatives face roughly 3–6% lifetime risk — elevated but still a minority probability.

Known genetic contributors:

GBA gene variants (Gaucher disease gene): The most common genetic risk factor for Parkinson’s disease and PDD. Carried by approximately 5–15% of PD patients. GBA variants increase risk of PD and may correlate with faster cognitive progression. Adult children with a family history of PD who are considering genetic testing can be referred to a genetic counselor.
SNCA gene (alpha-synuclein) duplications/triplications: Very rare but cause early-onset, severe PD with dementia. These familial cases account for a small minority of all PDD.
LRRK2 gene: The most common Mendelian cause of PD; usually presents without early dementia, but some LRRK2 variants increase DLB/PDD risk.

What should adult children do? There is no proven preventive treatment that makes genetic testing actionable in PDD genetics at this time — a positive GBA test, for example, identifies elevated risk but does not change management today. Families interested in this information should pursue it through a certified genetic counselor (ask the neurology team for a referral) who can discuss implications in context before testing.

Risk reduction for family members: While no guaranteed prevention exists, the factors associated with lower PD/PDD risk in population studies include: regular vigorous exercise, not smoking, maintaining healthy weight, good cardiovascular risk factor control, and possibly high caffeine intake (though this is not established enough to recommend). These lifestyle habits have benefits far beyond PDD risk.

Reproductive considerations

Parkinson's disease dementia (PDD) is a condition that occurs in people who have had Parkinson's disease for many years, typically developing after age 65. Pregnancy concurrent with PDD is essentially not a recognized clinical scenario. If you are a caregiver of reproductive age, medications dispensed at home (rivastigmine patches, memantine) should be stored safely away from children and handled with gloves if you are pregnant — accidental skin contact with rivastigmine patches in particular should be avoided. Genetic risk for PDD is primarily through Parkinson's disease genetics (GBA, LRRK2); family members with strong family histories may wish to discuss genetic counseling with a neurologist.

Glossary of Key Terms

Medical discussions about Parkinson's disease dementia involve specialized terms that can be confusing. This glossary explains the most important ones in plain language.

Parkinson's Disease Dementia (PDD): A dementia that develops in a person who already has Parkinson's disease. By definition, PDD occurs at least one year after Parkinson's motor symptoms begin. It is caused by the same Lewy body pathology that drives Parkinson's, but the cognitive symptoms become the dominant concern. Roughly 50–80% of people with Parkinson's disease eventually develop some degree of dementia, typically appearing 10–15 years after motor onset.
Dementia with Lewy Bodies (DLB): A closely related condition in which dementia and cognitive fluctuations appear before or at the same time as motor symptoms — or within one year of motor onset. PDD and DLB share the same Lewy body pathology; the distinction is primarily based on timing. DLB tends to have more prominent visual hallucinations and fluctuations earlier in the course, while PDD tends to appear in someone who has lived with Parkinson's for many years.
Lewy Body: Abnormal protein deposits (primarily made of alpha-synuclein) that accumulate inside nerve cells in both Parkinson's disease and DLB. Lewy bodies disrupt normal brain cell function and eventually cause cell death. In PDD, Lewy bodies spread beyond the motor regions of the brain to areas controlling memory, attention, and behavior over time.
Alpha-Synuclein: The main protein that misfolds and clumps to form Lewy bodies. Research into therapies that prevent or clear alpha-synuclein aggregation is an active area of PDD and Parkinson's disease dementia drug development. Several investigational agents targeting alpha-synuclein are in clinical trials as of 2024–2025.
Cholinesterase Inhibitor: A class of medication that slows the breakdown of acetylcholine, a chemical messenger important for memory and attention. In PDD, the brain's cholinergic system is more severely damaged than in Alzheimer's disease. Rivastigmine (Exelon) is the only FDA-approved cholinesterase inhibitor for PDD. Donepezil (Aricept) is sometimes used off-label. These medications do not stop disease progression but can modestly improve cognitive symptoms and reduce behavioral disturbances.
Rivastigmine (Exelon): The only medication with FDA approval specifically for Parkinson's disease dementia (approved 2006). Available as a twice-daily capsule or a 24-hour skin patch. The patch is preferred for most people because it causes fewer gastrointestinal side effects (nausea, vomiting) than the capsule. Common side effects include nausea, loss of appetite, and weight loss. It takes 3–6 months to see the full effect; benefit is often modest but meaningful for daily function.
Memantine (Namenda): A medication that works differently from cholinesterase inhibitors — it blocks a receptor called NMDA to reduce abnormal glutamate activity, which can damage brain cells. Memantine is FDA-approved for moderate-to-severe Alzheimer's dementia and is often used off-label in PDD for the same stage. It is generally well tolerated. Some people take both rivastigmine and memantine together.
Pimavanserin (Nuplazid): An FDA-approved medication specifically for Parkinson's disease psychosis (hallucinations and delusions) that does not worsen motor symptoms. Traditional antipsychotic medications are usually avoided in PDD because they block dopamine receptors and can severely worsen Parkinson's motor symptoms, sometimes causing a life-threatening neuroleptic malignant syndrome-like reaction. Pimavanserin works through serotonin receptors instead and carries a Boxed Warning for increased mortality in elderly patients with dementia-related psychosis.
MoCA (Montreal Cognitive Assessment): A brief cognitive screening test that takes about 10 minutes to administer. It assesses memory, attention, language, visuospatial abilities, and executive function. A score of 26–30/30 is normal; lower scores suggest cognitive impairment. MoCA is more sensitive than the MMSE for detecting the mild executive and visuospatial deficits seen early in PDD. Your neurologist may repeat MoCA at annual or semiannual visits to track change over time.
MMSE (Mini-Mental State Examination): An older but widely used 30-point cognitive screening test. It is less sensitive than MoCA for early or mild cognitive impairment in Parkinson's disease, but is useful for tracking moderate-to-severe dementia. It takes about 5–10 minutes. Many studies and clinical trials use MMSE as a primary outcome measure, so you may see it referenced when comparing trial results.
Visuospatial Dysfunction: Difficulty judging spatial relationships, distances, or interpreting what is seen visually, even though the eyes themselves are normal. In PDD, visuospatial problems often appear early and can cause difficulty judging steps, pouring liquids accurately, parking a car, or reading a map. Visuospatial dysfunction is more prominent in PDD and DLB than in Alzheimer's disease.
Fluctuating Cognition: A hallmark feature of Lewy body dementia in which alertness and cognitive ability vary noticeably during the day and from day to day — often without any clear external cause. On a good day, the person may seem nearly like their old self; on a bad day, they may be very confused or drowsy. These fluctuations are not always predictable and can be mistaken for medication side effects, infections, or strokes.
REM Sleep Behavior Disorder (RBD): A sleep condition in which the normal paralysis that prevents acting out dreams during REM sleep is absent. People with RBD speak, shout, or physically move during dreams — sometimes punching, kicking, or falling out of bed. RBD is now recognized as a very early warning sign of Parkinson's disease and Lewy body dementia, sometimes appearing 10–20 years before motor or cognitive symptoms. Clonazepam (low dose, at bedtime) and melatonin are the most used treatments.
DaTscan (Dopamine Transporter SPECT): A nuclear medicine brain imaging test that shows whether the brain's dopamine system is intact. In PDD and DLB, the dopamine system is damaged, producing an abnormal pattern rather than the normal bilateral signals. DaTscan is FDA-approved to help distinguish DLB from other dementias (particularly Alzheimer's disease) when the diagnosis is uncertain. It does not distinguish PDD from DLB, as both show abnormal results.
GBA Gene: The gene encoding the enzyme glucocerebrosidase. Heterozygous variants in GBA (e.g., N370S, L444P) are the most common genetic risk factor for Parkinson's disease, affecting roughly 5–15% of people with Parkinson's. GBA-related Parkinson's disease is associated with higher rates of cognitive impairment and dementia. GBA is a target for investigational therapies including ambroxol, which is in clinical trials for PDD and GBA-Parkinson's disease as of 2024.
Neuropsychiatric Symptoms (BPSD): Behavioral and psychological symptoms of dementia, which in PDD commonly include visual hallucinations, paranoid delusions, apathy, depression, anxiety, agitation, and sleep disturbances. These symptoms are often more distressing to caregivers than the cognitive deficits themselves, and addressing them is a major focus of PDD management. Non-drug strategies (structured routines, simplifying the environment, caregiver communication techniques) are first-line before medications are considered.
Carbidopa-Levodopa (Sinemet): The most effective medication for Parkinson's motor symptoms. In PDD, there is a complex balance: levodopa treats stiffness, slowness, and tremor, but high doses can worsen hallucinations and psychosis. The goal in PDD is to use the lowest dose that maintains adequate motor function while minimizing psychiatric side effects.

Key sources

Based on the Movement Disorder Society Task Force criteria for Parkinson's disease dementia; the EXPRESS trial of rivastigmine and FDA prescribing information; the HARMONY trial of pimavanserin in dementia-related psychosis; NICE guidance NG71 (Parkinson's) and NG97 (dementia); AAN practice guidance; Lewy Body Dementia Association treatment guidance; investigational programs including blarcamesine (NCT03774459), neflamapimod (NCT04001517, NCT05869669), and ambroxol (NCT02914366); and ClinicalTrials.gov registry data. This guide is educational and is not a substitute for advice from your own medical team.

A Research Guide forParkinson's Disease Dementia

⚡ Quick Start — If You Read Nothing Else

Understanding Parkinson's Disease Dementia

PDD and dementia with Lewy bodies — two sides of one coin

What PDD looks like

Why it happens

First steps after a diagnosis

How common is it, and when does it happen?

How PDD Progresses: A Realistic Guide to the Disease Trajectory

What to expect over time

Understanding the Day-to-Day Experience of PDD

What it can feel like, day to day

Common questions, honest answers

The biology, a little deeper

Questions to ask your doctor

Diagnosis & Workup

How the diagnosis is made

Cognitive testing, explained

Specialized tests

Understanding Your Cognitive Test Results

Distinguishing PDD from look-alikes

Questions to ask your doctor

Treatment

Cholinesterase inhibitors — the mainstay

Memantine

Treating hallucinations and delusions safely

Understanding the medication-safety logic

Non-motor symptoms

What to expect from rivastigmine

Medication Management in PDD: Timing, Balance, and Practical Tips

Managing fluctuations

Non-Drug Strategies That Genuinely Help in PDD

Non-drug approaches

Questions to ask your doctor

Advanced Disease & Clinical Trials

A note on palliative care

Palliative Care and Comfort-Focused Care in PDD

Managing advanced disease

Safety Considerations in PDD: When to Act Without Waiting

Serious warning signs requiring same-day or emergency evaluation

Key medication safety reminders for PDD

Safety in advanced disease

Emotional and relationship care

Understanding Clinical Trials in PDD and How to Find Them

>Clinical trials and the research pipeline

Questions to ask your doctor

Exercise, Sleep, and Nutrition in PDD

Living Well & Support

Practical Daily Function Strategies in PDD

Behavioral symptoms — what helps

Daily strategies

Communicating Effectively With Someone Who Has PDD

Communicating and connecting

Driving and Mobility Independence: Navigating Difficult Transitions

Driving and safety

Planning ahead

Mountain West / Utah

Caregiver self-care and respite

Caregiver Resilience and Preventing Burnout in PDD

Financial and practical assistance

National organizations

Peer Support, Community, and Connecting With Others Affected by PDD

Making the most of organizations and online information

International access

Planning Ahead: Long-Term Considerations in PDD

Why Certain Treatments Don’t Work in PDD (And Why That Matters)

What has not worked

Genetics, Family Risk, and What to Tell Adult Children

Reproductive considerations

Glossary of Key Terms

Key sources

A Research Guide for
Parkinson's Disease Dementia